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ABSTRACT

p53 is a powerful tumor suppressor mutated in approximately half of all cancers.
Its mRNA is stabilized post-transcriptionally via complementary base pairing with the
transcript of its antisense gene, WRAP53α; without this interaction, p53 protein cannot
accumulate enough to carry out its many functions related to apoptosis, cell cycle arrest,
and DNA damage repair. Previous studies have shown that WRAP53α is induced in
response to DNA damage. The purpose of this study was to determine which transcription
factors might be responsible for this induction. After identifying three putative p53 binding
sites on the WRAP53α promoter, we used chromatin immunoprecipitation and site-directed
mutagenesis and found that p53 appears to bind several sites on the WRAP53α promoter in
a manner dependent upon the type of DNA damage. Similarly, we found that deletion of
these sites leads to a loss in induction. Although more experimentation is needed, these
findings indicate a regulatory positive feedback loop between WRAP53α and p53, which
may be important in mounting a proper DNA damage response. This positive feedback
loop may be used in targeted cancer therapy.
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PREFACE

Throughout the 20th century, progressive legislature concerning the availability of
potable water and edible food, safety of work and housing conditions, and effective control
of communicable diseases resulted in a major shift in leading causes of mortality for
nations across the globe, including the United States (Centers for Disease Control and
Prevention [CDC], 1999). In 1900, the top three leading causes of death among Americans
were, in order, pneumonia, tuberculosis, and diarrheal diseases (CDC, 2018). As life
expectancy increased due to public health efforts, the nature of morbidity and mortality
changed, and the external agents of death that had once been most fatal were surpassed by
systematic failure of the very bodies people inhabited. By 1950, the number one killer of
Americans was “diseases of the heart,” followed by malignant neoplasms, and, finally,
“vascular lesions affecting central nervous system” (later categorized as cerebrovascular
diseases, e.g., stroke) (CDC, 2018). Nearly two decades into the twenty-first century, these
leading causes of death have not changed significantly; in 2016, 635,260 Americans died
of cardiovascular disease and 598,038 died of cancer (CDC, 2016b).
Although the total number of deaths per year has risen due to an aging population
structure, cancer is the only leading cause of death that has increased percentage-wise, as
adjusted rates of cardiovascular disease, stroke, and accident-related deaths (responsible
for the 4th greatest number of deaths) have either stabilized or decreased since 1950 (CDC,
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2002; CDC, 2009; CDC, 2013). This phenomenon is not unique to the United States.
Cancer remains the number two most common cause of death worldwide, killing an
estimated 9.6 million people in 2018, which is the equivalent of one in six deaths (World
Health Organization [WHO], 2018a). In 2012, it was predicted that 14.1 million new cases
of cancer were diagnosed around the world (Ferlay et al., 2015), and grim current global
projections suggest that by 2030, there will be over 20 million new cases of cancer annually
(Bray, Jemal, Grey, Ferlay, & Forman, 2012).
These projections indicate a paradox wherein the improvements made in
preventing, detecting, and treating other major causes of death are not translating to
preservation of life among cancer patients, despite the National Cancer Institute (NCI)
receiving, for the 2019 fiscal year, $5.74 billion of federal funds for research—a 1.4%
increase compared to 2018. (NCI, 2018). Furthermore, it is expected that by 2020, if not
sooner, the annual CDC mortality report will show cancer deaths exceeding cardiovascular
disease deaths for the first time ever (CDC, 2016a).
Preventing, diagnosing, and treating cancer is made more complicated by the fact
that trends in cancer morbidity vary by sex, race, age, socioeconomic status, and country
of residence, in addition to more complex lifestyle factors (Ferlay et al., 2015; WHO,
2018a). Such factors include tobacco use, physical inactivity, poor diet, obesity, and
alcohol consumption. Other external factors that, alongside lifestyle factors, account for 30
- 50% of cancer cases include viral infections, environmental pollutants, occupational
toxins, and exposure to radiation (WHO, 2018b). But these extrinsic factors do not account
for a major, less understood driver of carcinogenesis that often works synergistically
alongside environmental and lifestyle factors: genetic mutations (NCI, 2015).

vii

It is my aim to contribute, however small my impact, to further understanding this
elusive genetic component of cancer—to establish the mechanisms by which mutations
promote tumor growth, to isolate the genes that yield this change, and to tease out the
proteins that catalyze it, in order to inform treatment and prevention strategies, change
public health policy, or aid in the understanding and discovery of novel cancer therapy.
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CHAPTER I
INTRODUCTION

p53 is a frequently mutated tumor suppressor
As the genetic etiology of cancer has become more widely researched, p53, a
powerful tumor suppressor, has been implicated as the most frequently mutated gene of
cancer (not adjusted for tumor type) (Kandoth et al., 2013). Studies predating the age of
genomics approximated that a p53 mutation occurs in 50% of all tumors (DeFromentel &
Soussi, 1992); more recent findings have validated early estimates in addition to unveiling
a poorer prognosis associated with such mutations (Kandoth et al., 2013; Olivier, Hollstein,
& Hainaut, 2010;). Genomic analysis of tumors has even prompted the macabre prediction
that p53-mutant cancers will be responsible for the deaths of 500 million people currently
alive (assuming therapeutic strategies do not change) (Kastenhuber & Lowe, 2017).
The frequency at which p53 mutates was evident almost immediately after its
discovery. In 1979, the p53 protein—named for its molecular weight, which is 53
kilodaltons (kDa)—was first identified as a protein associated with simian virus 40 (SV40)
infection, specifically the viral large T antigen (TAg) protein (Lane & Crawford, 1979;
Soussi, 2010). At the time, it was unknown that deactivation of p53 is a consequence of
SV40 viral infection (Cooper, 2000)—as a result, the interaction of p53 and the TAg was
thought to be a viral replication strategy, and the gene was subsequently categorized as a
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proto-oncogene (Soussi, 2010). Such assumptions were supported by experiments
transfecting tumor-derived p53—not known to be mutant—into cells alongside the murine
Ras oncogene and observing rapid proliferation and foci formation in vitro (Soussi, 2010).
By the late eighties, the misnomer was clarified, and wild-type p53 was found to
be a tumor suppressor, although in the mutant form, p53 has oncogenic properties that
complicate a clear distinction between proto-oncogene and tumor suppressor (Finlay,
Hinds, & Levine, 1989; Soussi, 2010; Soussi & Wiman, 2015). As the body of work
regarding p53 has grown, its numerous interactions have been gradually uncovered, and it
continues to dominate scientific literature.

p53 is involved in a variety of cellular functions
As a tumor suppressor, p53 protein is maintained at low levels until genotoxic stress
permits protein accumulation. p53 then carries out a multitude of tasks related to regulation
of progression through the cell cycle, repair of damaged deoxyribonucleic acid (DNA),
control of target gene transcription, stabilization of the genome, and mediation of numerous
and diverse biological processes, such as aging, angiogenesis, apoptosis, autophagy,
chromosomal segregation, embryo implantation, metabolic regulation, and senescence
(Beckerman & Prives, 2010; Kay, Jeyendran, & Coulam, 2006; Murray-Zmijewski, Slee,
& Lu, 2008; Vogelstein, Lane, & Levine, 2000; Vousden & Prives, 2009;). In fact, it is
estimated that p53 directly regulates approximately 500 target genes—and this estimate
does not account for indirect effects of p53 stabilization (Aubrey, Kelly, Janic, Herold, &
Strasser, 2018). Figure 1.1 represents the expansive p53 network.
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Figure 1.1. p53 is involved in a vast array of cellular functions. p53 interacts with a
diverse network of genes (pictured as nodes). Each interaction is represented by a blue line
(direct p53 input) or a red line (direct p53 output). The interconnectedness of p53 protein
interactions and the downstream effects on multiple cellular processes emphasize the
inactivation of p53 as a major event in tumorigenesis. *Image taken from Kastenhuber &
Lowe (2017)
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p53 promotes each step of intrinsic apoptosis
Despite its ability to regulate many genes in varying pathways, p53 remains first
and foremost a tumor suppressor, preventing the propagation of cancerous mutations
through three main mechanisms: DNA damage repair, cell cycle arrest, and apoptosis. In
humans, apoptosis occurs through two classes of pathways: an extrinsic (death-receptor)
pathway and an intrinsic (mitochondrial) pathway (Aubrey et al., 2018; Strasser,
O’Connor, & Dixit, 2000) (Figure 1.2). Although both pathways end with the activation of
cysteine-aspartic protease (caspase)-3 and fragmentation of the cell, the intrinsic pathway
is p53-dependent and is mediated by the Bcl-2 family of proteins, which ultimately cause
mitochondrial permeabilization (Aubrey et al., 2018).
The Bcl-2 family of proteins consists of namesake Bcl-2 proteins, which act as antiapoptotic proteins and promote cellular survival, and Bh3-only proteins, which act as proapoptotic proteins, directly activating death effector proteins such as Bax (Aubrey et al.,
2018). In unstressed cells, Bcl-2 proteins block p53-dependent apoptosis by inhibiting
BAX, therefore preventing apoptosis (Aubrey et al., 2018). However, in stressed cells, p53
protein is stabilized and promotes transcription of two genes, p53 Upregulated Modulator
of Apoptosis (PUMA) and NOXA, which both encode proteins among the Bh3-only class
of Bcl-2 pro-apoptotic proteins—these, along with p53, also upregulate BAX (Aubrey et
al., 2018), effectively tipping the cellular fate in favor of apoptosis.
At the mitochondria, p53 interacts with and inhibits anti-apoptotic Bh3-only proteins
(Vaseva & Moll, 2010). Importantly, p53 also acts as a transcription factor for BAX itself
(Menendez, Inga, & Resnick, 2009). Once apoptosis has started, Bax protein, which is
normally located in the cytosol, also travels to the mitochondria to enhance cytochrome c
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release and MOMP (Wolter et al., 1997; Yee & Vousden, 2005). Figure 1.3 depicts the
chain of events that lead to apoptosis, each step of which is upregulated by the stabilization
of p53.

Figure 1.2. Apoptosis is mediated through extrinsic and intrinsic pathways. The extrinsic
pathway, also called the “death-receptor pathway,” occurs when death receptors at the
plasma membrane are ligated, favoring accumulation of adapter proteins such as Fasassociated protein with death domain (Fadd); this complex forms a death-inducing complex
(DISC), which activates caspase-8, leading to subsequent activation of caspases 3, 6, and
7, all of which cleave their substrates and lead to apoptotic fragmentation. On the contrary,
the intrinsic pathway, or “mitochondrial pathway,” is activated in response to extensive
cellular stressors, inhibiting anti-apoptotic proteins and leading to an accumulation of proapoptotic proteins in the cytoplasm (e.g., Bcl-2-like protein 4 [Bax]). These proteins create
pores on the surface of the mitochondria, leading to a mitochondrial outer membrane
permeabilization (MOMP) and a loss of membrane potential. Cytochrome c is released and
aggregates with apoptotic peptidase activating factor 1 (Apaf-1), forming an apoptosome
that activates caspase-9, which then activates caspases 3, 6, and 7, ultimately yielding a
similar effect to the extrinsic pathway. *Image taken from Reed (2000)
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p53 has also been shown to influence events further along in the apoptotic pathway.
For example, p53 expression upregulates cytochrome c release, activates caspase-3, and
promotes MOMP upon p53 protein’s translocation to the mitochondria in response to stress
(Mihara et al., 2003; Regula & Kirshenbaum, 2001).

Figure 1.3. p53 promotes each step of intrinsic apoptosis. Stabilization of p53 protein, as
a result of genotoxic stress, allows it to transcriptionally induce expression of PUMA and
NOXA, the protein products of which inhibit Bcl-2 proteins; p53 further promotes apoptosis
by directly activating death effector proteins Bax and Bcl-2 homologous antagonist/killer
(Bak) and may be involved in indirectly upregulating BCL2L11, which encodes an
additional Bh3-only protein known as Bim. p53’s eventual translocation to the
mitochondria during apoptosis also stabilizes the formation of the apoptosome, and p53
also transactivates APAF-1.*Image taken from Aubrey et al. (2018)

p53 achieves cell cycle arrest through both transcriptional activation and repression
Although p53 is most often thought of as a transactivator, another of its roles is to
repress transcription of a variety of genes, most notably those that encode the proteins
driving cell cycle progression; in fact, the number of genes downregulated by p53—when
accounting for indirect repression—is thought to be larger than the number upregulated by
6

p53 (2,700, as compared to 2,200) (Fischer, Steiner, & Engeland, 2014). One application
of this ability to both silence and activate transcription is evident in p53’s ability to interrupt
the cell cycle at the end of G1 and at the beginning and end of S-phase (Boggs & Reisman,
2006; Ginsberg, Oren, Yaniv, & Piette, 1990; Mosner et al., 1995; Reed, Alpers, Nowell,
& Hoover, 1986; Reich & Levine, 1984; Toyoshima, 2009) in addition to downregulating
genes which promote cell cycle progression, p53 simultaneously upregulates transcription
of CDKN1A, which codes for cell cycle inhibitor p21, for a two-pronged cell cycle arrest
(Chen, 2016) (Figure 1.4). To accomplish this, p53 protein binds two sites on the p21
promoter with high affinity (Chen, 2016). Once its transcription is increased, p21 protein
then binds and sequesters both the cyclin E/cyclin-dependent kinase (Cdk) 2 complex and
the cyclin D/Cdk4 complex, with the result being G1 arrest (Chen, 2016). When unbound,
Cdk2 phosphorylates the retinoblastoma protein (Rb); however, once sequestered by p21,
Rb is unable to be phosphorylated by Cdk2 and remains active, in turn sequestering E2F1
and silencing its transcriptional targets, which promote proliferation (Chen, 2016).
Furthermore, p21 binds proliferating cell nuclear antigen (PCNA), a protein required for
DNA synthesis, and prevents its assembly at the replication fork (Chen, 2016).
As a repressor, stabilized levels of p53 protein production lead to p53-mediated
downregulation of genes such as cyclins A and B, Cdk1, multiple cell division cycle (Cdc)
proteins, and DNA helicase monomer mini chromosome maintenance complex component
5 (MCM5), among others (Engeland, 2018). Recent studies have shown that the pathway
for indirect transcriptional silencing is identical in many p53 target genes. As p21 protein
binds to the cyclin E/Cdk2 and cyclin D/Cdk4 multimers, Rb target proteins experience
hypo-phosphorylation, leading to increased assembly of protein multimer DP, Rb-like,
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E2F4 and MuvB (DREAM) (Fischer, Quaas, Steiner, & Engeland, 2015). DREAM then
acts as a repressor, interacting with DNA at the cell cycle-dependent element (CDE) and
cell cycle gene homology region (CHR) areas of the target gene promoter and reversibly
silencing transcription (Fischer et al., 2015).

Routine p53 accumulation is a necessary step for regulation of the cell cycle
Accumulation of p53 protein to the extent that it affects transcription of target genes
is thought to be a response to DNA damage by ultraviolet (UV) radiation, hypoxia, or
oncogene activation (An et al., 1998; Bates et al., 1998; Vogelstein et al., 2000). However,
p53 is upregulated in unstressed cells at the beginning of S-phase so that it can initiate a
quick response in case damaged DNA is detected; as a result, mutations with tumorigenic
potential are not propagated through daughter cell replication (Boggs & Reisman, 2006;
Ginsberg et al., 1990; Mosner et al., 1995; Reed et al., 1986; Reich & Levine, 1984;
Takahashi, Polson, & Reisman, 2011).
This routine p53 accumulation is regulated by the dual transcriptional control of
CCAAT enhancer-binding protein β2 (CEBP-β2)—which permits transcription of p53—
and recombination signal binding protein for immunoglobulin kappa J (RBP-Jκ)—which
represses transcription (Boggs & Reisman, 2006; Boggs & Reisman, 2007; Polson,
Takahashi, & Reisman, 2010; Reisman & Boggs, 2007;). Additionally, ataxia
telangiectasia mutated (ATM), which is activated in response to DNA damage,
phosphorylates the human homolog of mouse double minute 2 (Mdm2); this
phosphorylation prevents Mdm2 from binding and marking p53 for proteasomal
degradation, while simultaneously phosphorylating p53 and activating it in preparation for
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a quick potential stress response (Chen, 2012; Chen, 2016). Kinases ATM- and Rad3related (ATR) and DNA-dependent protein kinase (DNA-PK) can also phosphorylate p53
and Mdm2 (Blackford & Jackson, 2017).

Figure 1.4. p53 acts a transcription factor, both activating and repressing, to achieve cell
cycle arrest. Initial DNA damage results in the activation of ATM, ATR, and DNA-PK,
which then phosphorylate p53 and Mdm2, the protein that tags p53 for degradation under
non-stressed conditions. These kinases may also activate Chk2, which inhibits Cdc25A
activation and subsequently prevents cell cycle progression. Once p53 is activated, it
represses transcription of several genes, including cyclins, Cdks, Cdcs, and MCM5, all of
which promote cell cycle progression and DNA replication. Additionally, p53 activates
p21. p21 directly inhibits PCNA, thereby preventing DNA replication. It also inhibits the
union of Cdk4 and cyclin D, which promotes cell cycle progression. Most interestingly,
p21 provides the mechanism for much of p53’s indirect transcriptional silencing: it
promotes the binding of Rb and E2F1. As a result, E2F1 is sequestered by Rb, which
prevents Rb from phosphorylating its other targets, namely p107 and p130. Under
conditions of hypo-phosphorylation, these targets are permitted to form the DREAM
complex, which binds to the CHR and CDE elements in many genes’ promoters. In this
diagram, proteins are represented by ovals; circles with “P” represent phosphorylation,
while a DNA cartoon represents a gene’s regulatory region. Arrows represent stimulatory
effects while bars represent repressive effects.
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p53 is an essential moderator of DNA damage repair
The role of p53 in DNA damage repair can be characterized in three main ways: by
transactivation of repair genes, by p53 protein interactions with repair enzymes, and by
indirect effects of p53 phosphorylation. The nature of the damage and subsequent
mechanism of repair are just two factors defining p53’s role, however, with most types of
damage, p53 contributes in all three ways (Williams & Schumacher, 2018) (Table 1.1).

Table 1.1. p53 facilitates DNA damage repair via transactivation of important genes,
protein interactions with repair proteins, and indirect effects.
Repair Type Gene Interaction Protein Interaction
Indirect
XPC
p48
Relaxes chromatin for
NER
XBP
XPC
damage detection by TFIIH
CSB
Represses APE1 to skew
OGG1
BER
APE1/REF-1
DNA damage response in
POLB
favor of apoptosis
Msh2
Role depends on postMMR
MSH2
Msh6
translational modifications
Rad1
Pushes cell toward
NHEJ
RAD51
Rad54
apoptosis instead of repair
Table 1.1. The type of DNA damage and resulting repair mechanism used ultimately
defines which genes p53 upregulates, in addition to which proteins it interacts with. p53
may also contribute to DNA damage repair in other ways, which are typically indirect,
depending on the type of damage. NER = nucleotide excision repair; BER = base excision
repair; MMR =mismatch repair; NHEJ = non-homologous end joining. *Table based on
Williams & Schumacher (2018)

Wild-type p53 protein is made up of six domains which carry out its many functions
Wild-type p53 protein is comprised of 393 amino acids and possesses unique
functional domains beyond its primary structure (Bai & Zhu, 2006) including two
transactivation domains and a proline-rich domain at the N-terminus, a DNA-binding
domain that constitutes the core of the protein, and regulatory and oligomerization domains
10

at the C-terminus which are responsible for nuclear localization and transcriptional
functions (Bai & Zhu, 2006; Kastenhuber & Lowe, 2017) (Figure 1.5). The majority of
p53-derived tumors are thought to arise from mutations in the core DNA-binding domain
(residues 100 - 300); such mutations impair p53’s ability to recognize binding motifs,
illustrating the importance of target gene regulation as a protecting force against
tumorigenesis (Bouaoun et al., 2016; Soussi & Wiman, 2015).

Figure 1.5. p53 protein is comprised of six main domains with six hotspot mutations.
Wild-type p53 protein is made up of two transactivation domains, a proline-rich domain, a
core DNA-binding domain, a linker domain, a tetramerization domain, and a C-terminal
domain with regulatory components. Residues are indicated by numbers, and the frequency
of mutation for each residue is symbolized by the height of the line above it. TAD =
transactivation domains 1 and 2; PRD = proline-rich domain; DBD = DNA binding
domain; OD = oligomerization domain; CTD = C-terminal domain; R = arginine; G =
glycine. *Image taken from Freed-Pastor & Prives (2012)
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p53 is recognized for its ability to bind DNA, acting as a transcription factor for
genes transcribed by RNA Polymerase II (RNAPII) (Beckerman & Prives, 2010). To do
this, the stabilized form of the protein enters the nucleus, where it forms a dimer that
subsequently dimerizes with another dimer, resulting in a tetramer, before binding to its
response element (RE) (Kitayner et al., 2006; McLure & Lee, 1998). Most p53 REs are
located upstream of the transcription start site (TSS), however, they can be located at the
TSS, within the transcribed region, or even within an exon (Beckerman & Prives, 2010;
Riley, Sontag, Chen, & Levine, 2008). p53 recognizes its RE with its highly specific DNA
binding domain (DBD) and with its C-terminal domain (CTD), which possesses a general
affinity for nucleic acids, allowing p53 to bind nonspecifically to both DNA and
ribonucleic acid (RNA) and, purportedly, to undergo scanning diffusion without binding
strongly until its RE is found (Beckerman & Prives, 2010; Liu & Kulesz-Martin, 2006;
McKinney, Mattia, Gottifredi, & Prives, 2004; Palecek et al., 1997; Tafvizi et al., 2008).

p53 isoforms have distinct physiological roles subject to regulation
p53 protein occurs in twelve different isoforms (Vieler & Sanyal, 2018), some of
which are being investigated as contributors to carcinogenesis (Bourdon, 2007). The p53
gene is a “dual gene” possessing two promoters with two different TSSs each. Promoter 1
yields full-length p53 with a TSS upstream of exon 1, in addition to a truncated protein
product (Δ40p53), with a TSS upstream of exon 4, starting with codon 40 (Bourdon, 2007;
Vieler & Sanyal, 2018). Two other isoforms (Δ133p53 and Δ160p53) are derived from the
second promoter with TSSs at codons 133 and 160, respectively. (Vieler & Sanyal, 2018).
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Additional protein variety originates from alternative splicing of intron 9, which can form
typical p53 protein, plus two isoforms that lack an oligomerization domain (Bourdon,
2007; Ghosh, Stewart, & Matlashewski, 2004; Vieler & Sanyal, 2018).
The isoform produced directly impacts the purpose of the p53 protein translated.
Δ40p53 lacks only one TAD and retains the functionality of full-length p53, acting upon a
specific set of genes (Vieler & Sanyal, 2018). Δ133p53, which lacks both TADs, the PRD,
and a significant amount of the DBD, may be involved in oligomerization only, conferring
promoter selectivity to the tetramer, as well interacting with related proteins p63 and p73
(Vieler & Sanyal, 2018). Δ160p53 is still being explored as a mutant p53 with gain-offunction (GOF) properties (Vieler & Sanyal, 2018) (Figure 1.6).

Figure 1.6. p53 is expressed in 12 different isoforms. The p53 gene possesses two distinct
promoters, each with two possible TSSs. Further alternative splicing leads to greater
protein diversity. The top panel shows the p53 gene’s canonical exons, as well as
alternative untranslated regions (UTRs) (checked boxes). The colors on the top panel
correspond to their respective coded domains on the bottom panel. The arrows on the
bottom panel indicate the starting point of each isoform, and the open boxes on the bottom
right represent further C-terminal isoform diversity. TAD I = transactivation domain 1;
TAD II = transactivation domain 2; PRD = proline-rich domain; HD = hinge domain; OD
= oligomerization domain; CTD = C-terminal domain. *Image taken from Vieler & Sanyal
(2018)
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It is thought that co-expression of different isoforms contribute to defined cellular
responses that ultimately govern cell fate (Joruiz & Bourdon, 2016). Some of these
isoforms are present in normal, healthy cells, suggesting that they serve specific purposes
and are subject to intentional regulation; this theory is supported by the fact that these
isoforms have unique expression profiles governing their localization at the tissue- and
cellular-level (e.g., p53ℽ is found both within the nucleus and cytoplasm, while p53ꞵ is
found almost exclusively in the nucleus) (Bourdon, 2007). This structural diversity is one
explanation for how p53 is able to participate in so many diverse cellular functions
(Bourdon, 2007).
p53 protein shares a similar structure, and an overlap in function, with related
proteins p63 and p73 (Kaghad et al., 1997; Schmale & Bamberger, 1997), however, unlike
p53, p63 and p73 are thought to have evolved into anti-proliferative proteins while
maintaining involvement in developmental functions within the cell (Bai & Zhu, 2006;
Irwin & Kaelin, 2001; Kastenhuber & Lowe, 2017). Although the three proteins share
similar structures and can all moderate cell cycle progression, p63 and p73 seem much
more crucial for early neuronal development, reproduction, and differentiation and are
regulated differently than p53—plus each protein maintains unique functions as well (for
example, p73 regulates the cell cycle at the M checkpoint and plays a role in mitosis, which
the other two proteins do not do) (Allocati, Di Ilio, & De Laurenzi, 2012).

Mutations in p53 contribute to carcinogenesis
p53 bears the moniker “guardian of the genome” because of its ability to stabilize
the genome with its diverse functions and prevent tumorigenesis (Lane, 1992; Vousden &
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Lu, 2002). But p53 mutations corrupt the guardian in a variety of ways, including downregulating wild-type processes, promoting oncogenic processes, and instilling dominant
negative tetramerization with wild-type protein (Dai & Gu, 2010).
Because p53 is the most commonly mutated gene in cancer, much attention has
been given to the protein product of mutant p53. The majority of p53 mutations are
missense, giving rise to a full-length protein with a single amino acid substitution, which
commonly occurs in the central DBD, required for binding DNA (Yue et al., 2017).
Although such substitutions have been documented at virtually every residue within the
DBD, one quarter of all mutations occur within the same six “hotspots”: R175, G245,
R248, R249, R273 and R282 (where R = arginine and G= glycine) (Yue et al., 2017)
(Figure 1.5). Such mutations affect p53’s ability to bind DNA, but do not impact its ability
to oligomerize properly with wild-type p53; as a result, mutant p53 successfully
tetramerizes in a dominant-negative manner with its wild-type counterpart, preventing
wild-type p53 from carrying out its functions (Yue et al., 2017). Interestingly, mutations in
most other tumor suppressors are largely deletion or nonsense mutations, resulting in no
expression of mutant proteins (Freed-Pastor & Prives, 2012).
Upon mutation, p53 often has an oncogenic effect on tumorigenesis, as opposed to
a neutral one (Yue et al., 2017). As a result, p53 mutants are beginning to be examined for
possible GOF activities that drive carcinogenesis (Brosh & Rotter, 2009) and promote
tumor survival, for example, an increased ability to enhance nuclear factor kappa-lightchain-enhancer of activated B cells (NF-κB) and tumor-favorable integrin and epidermal
growth factor receptor (EGFR) trafficking (P.A. Muller et al., 2009; Weisz et al., 2007).
Other gained functions may include developing a microenvironment that benefits
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cancerous lesions by enhancing chemoresistance, migration, and invasion, favoring a
disorganized tissue architecture, and altering cellular energetics to favor tumor
development (e.g., the Warburg effect) (Yue et al., 2017). Additionally, mutant p53 is
thought to contribute to metastasis via repression of tissue inhibitor of metalloproteinases
type 3 (TIMP-3), which normally keeps matrix metalloproteinases (MMPs) from
degrading the extracellular matrix (ECM) (Loging & Reisman, 1999).
Though wild-type p53 is barely expressed in unstressed conditions, these mutant
proteins often accumulate to alarming levels in tumors, becoming part of a novel network
of genes specific to mutant p53 (Yue et al., 2017). When maintaining its ability to regulate
target genes across the genome, mutant p53 acts as a transcription factor for a separate set
of genes than wild-type p53, many of which support tumor cell propagation, as opposed to
suppression (Freed-Pastor & Prives, 2012). Mutant p53 can also bind to the same promoters
wild-type p53 would bind to—but in this case, exerting the opposite effect (Freed-Pastor
& Prives, 2012).

p53’s influence on transcription extends beyond binding DNA
As a transcription factor, p53 most often depends on binding DNA to achieve a
transcriptional effect. However, p53’s effects can be attained in a variety of other ways.
For example, p53 recruits chromatin remodelers such as histone variant H2A.Z and histone
acetyltransferases (HATs) (Barlev et al. 2001; Gévry, Chan, Laflamme, Livingston, &
Gaudreau, 2007), which de-condense chromatin, thereby allowing RNAPII to transcribe
local genes. Furthermore, p53 has a role in actually initiating transcription—the binding of
the protein recruits several factors of the pre-initiation complex (PIC) including
transcription factor (TF)IIA and TFIIH (Beckerman & Prives, 2010; Ko & Prives, 1996;
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Xing, Sheppard, Corneillie, & Liu, 2001). Aside from just enhancing transcriptional
initiation, p53 contributes to elongation as well, by interacting with proteins that prevent
stalling, e.g., Cdk9 (Beckerman & Prives, 2010; Claudio et al., 2006; Radhakrishnan &
Gartel, 2006).
Although p53 is most often considered an activator, as seen by its involvement in
recruiting chromatin remodelers and additional transcription factors, in addition to
promoting the processivity and stability of RNAPII, p53 also acts as a repressor in an
estimated 15% of its direct interactions (Riley et al., 2008). This is mediated through four
main mechanisms. In some cases, p53 can compete with other transcription factors,
sterically hindering their access to DNA binding sites and leading to repression (Rinn &
Huarte, 2011). Aside from out-competing other activators, p53 can bind and sequester
them, preventing them from binding to DNA without ever being bound itself (Rinn &
Huarte, 2011). Additionally, although p53 typically has an effect of epigenetically
loosening chromatin through HAT recruitment, the protein can also recruit chromatin
repressor factors that silence transcription epigenetically, for example, histone deacetylase
(HDAC) (Rinn & Huarte, 2011). Finally, p53 can activate other pathways or transcription
factors that indirectly silence or repress transcription. An example of this is the p53/p21
interaction: when p53 activates p21 expression, p21 actually inhibits Cdks; this allows the
Rb protein to become increasingly phosphorylated, eventually binding to transcription
factor E2F and sequestering it, thereby preventing transcription of E2F targets (Rinn &
Huarte, 2011).
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p53 is transcriptionally regulated via factor binding at its promoter and RNA interactions
Although the p53 gene is mutated in half of cancers, tumors with wild-type p53 status
are often still characterized by p53 dysregulation (Bálint & Reisman, 1996; Boggs &
Reisman, 2006; Khoo, Mayer, & Fersht, 2009; Raman et al., 2000; Reisman & Boggs,
2007). As a result, altered p53 expression can accompany a cell’s transformation to a
cancerous phenotype (Vousden & Prives, 2009). The p53 promoter has no conserved
CAAT or TATAA sequences upstream of the transcription start site (Means & Farnham,
1990); rather, p53 is regulated by an initiator (INR) sequence (Smale & Baltimore, 1989),
which is thought to be preferential for genes with roles in routine biological processes (such
as p53) (Yang, Bolotina, Jiang, Sladek, & Martinez, 2007). Nevertheless, p53 gene
expression is tightly controlled by a combination of transcription factors, microRNAs
(miRNAs), and the transcript of WD Repeat-Containing Antisense to P53α (WRAP53α),
its antisense gene (Mahmoudi et al., 2009; Saldaña-Meyer and Recillas-Targa, 2011).
Transcription factors that are understood to interact with the p53 promoter include:
PF2, HoxA5, PBFI and PBFII, RBP-Jκ, and CEBP-β2 (Mahmoudi et al., 2009; Hale &
Braithwaite, 1995; Lee, Yu, Lee, & Park, 2001; Reisman & Loging, 1998; Polson et al.,
2010; Roy and Reisman, 1996; Saldana-Meyer & Recillas-Targa, 2011). In addition, Ybox binding protein (YB1), which shares many target genes with p53 but acts as its
antagonist, exerting the opposite effect, represses p53 transcription by binding to the p53
promoter and therefore advancing its own interactions with shared p53 target genes (Chin,
Ueda, Pastan, & Gottesman, 1992; Lasham, Lindridge, Rudert, Onrust, & Watson, 2000;
Lasham et al., 2003; M. Muller et al., 1998; Ohga et al., 1998; Shibao et al., 1999; Tamura
et al., 1995; Wang, Zambetti, & Suttle, 1997). Epigenetic regulation of p53 is moderated
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by CCCTC-binding factor (CTCF), which binds to the promoter and changes the chromatin
structure (Soto-Reyes & Recillas-Targa, 2010). In the absence of such interactions, the
chromatin remains condensed and p53 expression is repressed (Saldaña-Meyer et al.,
2014). Interestingly, c-myc can also act as a transactivator, as evidenced by mutant p53
protein accumulation in some tumors—this is more common in cells over-expressing cmyc, which often co-occurs with p53 mutations (Roy, Beamon, Bálint, & Reisman, 1994).

Post-transcriptional regulation of p53 mRNA is achieved by RNAs and protein interactions
The stability of the p53 transcript is regulated by its antiparallel gene, WRAP53α, the
first exon of which overlaps exon 1 of the p53 gene. Following transcription, these two
mRNA transcripts interact by what is thought to be a hybridization via complementary base
pairing, which confers stability to the p53 mRNA (Mahmoudi et al., 2009). Furthermore,
proteins such as HuR, L26, RPL26, nucleolin, and Wig-1 regulate p53 transcript stability
by binding to both the 5’ and 3’ UTRs (Farnebo, 2009; Vilborg et al., 2009; Vilborg,
Wilhelm, & Wiman, 2010). Notably, Wig-1 is a target gene of p53 protein, implicating it
in a positive feedback loop (Vilborg et al., 2009). Increasing interest in the role of miRNAs
as repressors has further implicated miR-125a and miR-125b as negative regulators of p53
expression based on their interaction with the 3’ UTR of the p53 transcript (Le et al., 2009;
Vilborg et al., 2010; Y. Zhang et al., 2009).

Mdm2 regulates levels of p53 in unstressed cells
The protein product of p53 is considerably unstable, with a half-life of 20-25
minutes (Mosner et al., 1995; Reich & Levine, 1984). This limited half-life is ideal for
constitutive expression in cells not undergoing stress and is achieved by Mdm2—the
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transcription of which is actually activated by p53 protein—binding to p53 and catalyzing
its degradation through ubiquitin-proteasome tagging (Barak, Juven, Haffner, & Oren,
1993; Oren & Rotter, 1999; Toledo & Wahl, 2006) (Figure 1.7).

Figure 1.7. Mdm2 keeps p53 levels low in unstressed conditions. This diagram illustrates
major functions of Mdm2 and p53, as well as their relationship to each other. Under
unstressed conditions, Mdm2 binds p53 and marks it for degradation. Upon genotoxic
stress, p53 and Mdm2 are phosphorylated by ATM, ATR, and DNA-PK, which permits
p53 to carry out its functions—one of which is transactivation of Mdm2. *Image taken
from Alarcon-Vargas & Ronai (2002)

Post-translational modifications of p53 are redundant, reversible, and context-dependent
Although transcriptional and post-transcriptional regulation of p53 do occur, the most
well-studied mode of regulation comes from post-translational modifications (PTMs) of
p53 protein in response to genotoxic stress. Such modifications provide a way to fine-tune

20

p53 protein localization, stability, and function by altering protein structure and chemistry
or changing binding domain availability (Marouco, Garabadgiu, Melino & Barlev, 2013).
The amino- and carboxy-termini are heavily populated by serine (S), threonine (T), and
lysine (K) residues, which undergo extensive PTM including modifications that generally
contribute to p53 degradation, such as ubiquitination, neddylation, sumoylation, and
methylation, in addition to modifications that stabilize p53 protein, such as
phosphorylation, acetylation, and some methylation (Marouco et al., 2013). Additionally,
more novel types of PTM can occur, such as β-linked N-acetylglucosamine acylation (OGlcNAcylation), adenosine diphosphate- (ADP) ribosylation, hydroxylation, and βhydroxybutyrylation (Liu, Tavana, & Gu, 2019). As a rule, p53 PTMs are characterized by
certain trends: redundancy, as they can often occur at more than one location, upon more
than one amino acid; reversibility, as each modification is reversible, given the correct set
of functional enzymes; and, finally, context-dependence, as the effect achieved by certain
PTMs may rely on variables including site, type of modification, and even which
modifications have previously occurred (Liu et al., 2019). Major PTMs of p53 protein are
plotted in Figure 1.8.
Ultimately, the result of PTMs is that protein stability or function can be controlled
(Kastan, Onyekwere, Sidransky, Vogelstein, & Craig, 1991; Vousden & Prives, 2009).
This is most notable in the event of genotoxic stress, wherein the first step of a p53 response
is protein stabilization and accumulation, prior to transactivation of relevant genes leading
to apoptosis, cell cycle arrest, and DNA damage repair (among other effects). Such stimuli
can include: chemical or physical DNA damage, genomic instability, DNA synthesis
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inhibition, telomere erosion, hypoxia, oncogene activation, or nutrient deprivation
(Marouco et al., 2013).

Figure 1.8. Post-translational modifications of p53 provide a complex mechanism of
control. Sites for phosphorylation (purple), ubiquitination (red), sumoylation (violet),
neddylation (lime green), acetylation (blue-green), methylation (blue), O-GlcNAcylation
(orange), ADP-ribosylation (mustard), hydroxylation (blue/violet), and βhydroxybutyrylation (turquoise) are shown. Amino acids and their relative location in the
protein are indicated by an alphanumeric sequence, and consequences of PTMs are given
for select residues. Additionally, different p53 protein domains are shown. The figure is
shown from the N-terminus (1) to the C-terminus (393) and is not drawn to scale. T =
threonine; K = lysine; R =arginine; D = aspartic acid; S = serine; TAD = transactivation
domain; PRD = proline-rich domain; DBD = DNA binding domain; TD = tetramerization
domain; CTD = C-terminal domain. *Image taken from Liu et al. (2019) and based on Dai
and Gu (2010) and Gu and Zhu (2012)

Phosphorylation of p53 protein largely occurs on S and threonine T residues—such
sites are abundant in the N-terminal domain, though they are found in all domains—and
generally produces a stabilizing effect on the protein in response to genotoxic stress,
although some residues are constitutively phosphorylated in unstressed cells (Liu et al.,
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2019). Notably, in response to DNA damage, kinases ATM and ATR can phosphorylate
p53 at S18 and S20, while simultaneously phosphorylating its antagonist, Mdm2, which
results in concurrent p53 activation and Mdm2 inactivation. (Liu et al., 2019). Apoptosis
can be favored over senescence or DNA damage repair with additional phosphorylation of
S46 in the face of severe genotoxic stress (Liu et al., 2019).
While ubiquitination frequently results in proteasomal degradation, another effect can
include regulation of localization, protein interaction, and activity (Liu et al., 2019). The
canonical example of p53 ubiquitination, in unstressed cells, Mdm2 keeps p53 levels
constitutively low by poly-ubiquitination of as many as six lysines in the CTD (Liu et al.,
2019). p53 ubiquitination can be regulated by herpes virus-associated ubiquitin-specific
protease (HAUSP), as well as by Mdm2, which auto-ubiquitinates, marking itself for
proteasomal degradation (Brooks & Gu, 2006). Mono-ubiquitination also seems to serve a
purpose independent of degradation and can be mediated by Mdm2 in order to influence
nuclear export of p53 (Brooks & Gu, 2006). Other small molecules, such as small
ubiquitin-like modifier (SUMO) and neural precursor cell expressed developmentally
downregulated protein 8 (NEDD8), interact with the protein much as ubiquitin would, and
also occur at lysines, though they seem to direct p53 protein’s ability to transactivate its
target genes rather than its stability or localization (Liu et al., 2019).
Acetylation of lysines is largely associated with epigenetic remodeling of chromatin
but does occur in p53 protein as well, by CREB-binding protein (CBP) and E1A binding
protein (p300), the very same HATs that acetylate chromatin, (Liu et al., 2019). Typically,
acetylation leads to p53 protein stability (Marouco et al., 2013). This effect can be direct
or indirect—for example, an overlap in acetyl and ubiquitin group chemistry means that
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acetyl groups can sterically hinder or out-compete ubiquitin groups, preventing
ubiquitination at these sites (Liu et al., 2019).
Acetylation can also give specificity to p53’s many functions by promoting certain p53
functions while hindering others (Liu et al., 2019). For example, in response to UV-induced
DNA damage, the HAT p300/CBP-associated factor (PCAF) acetylates K320 (Marouco et
al., 2013). This increases p53 affinity for the p21 promoter, resulting in cycle arrest as
opposed to apoptosis, because it interferes with p53 tetramerization—which is absolutely
necessary in low-affinity apoptotic promoters, though is not critical in high-affinity
promoters, such as that of p21 (Marouco et al., 2013). Interestingly, deletion of one
acetylation site had no effect on p53 target gene transactivation, but deletion of all sites
impaired p53’s ability to act as a transcription factor, indicating that the exact location of
acetylation may not be important (Marouco et al., 2013).
As with acetylation, lysine and arginine methylation of p53 protein often occurs
alongside with methylation of chromatin and can be mediated by the same enzymes (Liu
et al., 2019). Methylation occurs on at least four lysine residues in p53’s C-terminal, and
depending on whether mono-, di-, or tri-methylation occurs, methylation can enhance or
impede a p53 response (Marouco et al., 2013).

WRAP53α is located antiparallel to p53
Recent studies have examined p53 gene expression through the lens of regulatory
RNAs. It is thought that 20% of all human genes overlap, and that 70% of mammalian
genes undergo antisense transcription (Mahmoudi et al., 2009). A seminal paper by
Mahmoudi et al. (2009) identified one such natural antisense transcript (NAT) as a
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mechanism of p53 post-transcriptional regulation. Located on chromosome 17p13.1, p53’s
antisense gene—WRAP53 (Figure 1.9)—undergoes extensive alternative splicing;
furthermore, the WRAP53 gene possesses three start exons, denoted by α, β, and γ, resulting
in as many as 17 variants (Mahmoudi et al., 2009). The first exon of WRAP53α overlaps
the first exon of the p53 gene by 47-227 bp, depending on which of p53’s TSSs is used
(Mahmoudi et al., 2009) (Figure 1.10). Additionally, although it will not be further
discussed, exon 1 of the WRAP53γ variant also overlaps a previously identified long noncoding RNA (lncRNA), Hp53int1, in p53’s first intron (Reisman, Bálint, Loging, Rotter,
& Almon, 1996).

Figure 1.9. WRAP53 is p53’s antisense gene. A diagram of chromosome 17p13 is shown,
with the sense strand indicated by (+) and the antisense strand indicated by (-). The
direction of transcription is shown by the arrowhead. Neighboring genes ATP1B2 and
EFNB3 are represented as black arrows flanking the p53 (purple) and WRAP53 (red)
overlap. The protein product of some WRAP53 transcripts is a WD40-like protein and is
represented by the lime green box, showing its N- and C-terminals. *Image taken from
Mahmoudi et al. (2009)

Although WRAP53 encodes a WD40-like protein implicated in Cajal body
formation and telomerase function (Mahmoudi et al., 2010), this protein is largely
attributed to translation of the WRAP53β variant, as small interfering RNA (siRNA)mediated knockdown of WRAP53α did not lead to a decrease in Wrap53 protein levels
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(Mahmoudi et al., 2009; Kim, Lee, & Park, 2018). On the contrary, although the WRAP53α
variant does possess protein-coding exons, the protein product appears to be truncated and
non-functional (Mahmoudi et al., 2009), however, it is worth noting that research
comparing activities of the truncated WRAP53α protein and full-length WRAP53β protein
does not yet exist and could reveal a different story.

Figure 1.10. The WRAP53 gene has three start exons, one of which, α, overlaps the p53
first exon. The organization of antisense genes p53 and WRAP53 is represented.
Untranslated start exons 1γ, 1α, and 1β are shown by red boxes, and complementary strand
hybridization to their antisense transcript is depicted by dotted lines. Translated regions of
WRAP53 are represented by yellow boxes, with the beginning of the coding region
indicated by “ATG” and termination of the coding region indicated by “TAA”. The image
is not drawn to scale. p53 exons are shown in blue, and major and minor TSSs are given
for both p53 and WRAP53α. *Image taken from Mahmoudi et al. (2009)
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WRAP53α induction is required for p53 transcript stability
Studies in WRAP53 expression conducted by J. Yuan et al. (2011) have shown that
WRAP53α is induced in response to cisplatin-mediated DNA damage in U2OS cells.
Furthermore, the function of this induction has been examined and it was found that
elevated WRAP53α mRNA transcript levels stabilize the p53 message posttranscriptionally by interacting—likely through complementary base pairing—with the 5’
UTR of p53 mRNA (Mahmoudi et al., 2009) (Figure 1.11). Such post-transcriptional
upregulation is limited to the α-form of WRAP53 and has been confirmed by siRNA
mediated knock-down of WRAP53α, during which the p53 mRNA transcript was degraded
before significant protein accumulation occurred, preventing transactivation of p53 target
genes (Mahmoudi et al., 2009). Interestingly, this stabilizing event can take place with only
a slight induction in WRAP53α: a quantification of transcripts through quantitative
polymerase chain reaction (qPCR) showed that with a transcript ratio of one WRAP53α for
every 100 p53, the p53 mRNA was still upregulated enough to elicit a DNA damage
response (Mahmoudi et al., 2009), supporting a model wherein a single WRAP53α
transcript transiently interacts with multiple p53 transcripts.
Although we now know that WRAP53α is induced in response to certain types of
DNA damage, and that this induction may be responsible for stabilizing p53 mRNA long
enough for it to actually become translated, the purpose of this thesis is to detail the process
of identifying which binding factors may be responsible for this crucial induction of
WRAP53α. Our findings indicate that the p53 protein itself binds to a specific site or sites
in the WRAP53α promoter and induces its expression in response to DNA damage as part
of an apparent positive feedback loop.
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Figure 1.11. WRAP53α regulates p53 post-transcriptionally. The sense and antisense
strands of the p53/WRAP53α overlap on chromosome 17p13.1 are indicated, with WRAP53
shown in red and p53 shown in blue. The first exon overlap is indicated by vertical black
lines. Following transcription, the mRNAs are thought to hybridize, with WRAP53α
protecting p53 from degradation. Upon knockdown or siRNA-mediated blockage of the
hybridization, p53 mRNA is degraded quickly, and p53 protein never accumulates enough
to act on its targets. However, overexpressing WRAP53α mRNA leads to increased p53
mRNA and an abundance of p53 protein that is able to exert its effects on target genes.
*Image taken from Farnebo (2009)
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CHAPTER II
MATERIALS AND METHODS
1. Tissue Culture
Human cell lines U2OS, SAOS-2, HCT116, and HCT116-p53 K/O, an HCT116
derivative line with a targeted homologous recombination, resulting in knock-out p53
(Bunz et al., 1999) were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) and
supplemented with 10% fetal bovine serum (FBS) (Atlas Biologicals), 2 mM L-glutamine,
3.5 g/L glucose, 100 U/µL penicillin, and 100 µg/µL streptomycin (Sigma-Aldrich). The
cells were maintained at 37°C with 6% CO2 in a humidified incubator. All experiments
took place when cells reached 80% confluency. In order to transfer, cells were trypsinized
with 0.25% trypsin-ethylenediaminetetraacetic acid (EDTA) solution (Sigma-Aldrich).
Cells lines were picked based on tissue type and p53 status (Table 2.1).

Table 2.1. Four cell lines were picked based on tissue type and p53 status.
p53 status
Wild-type p53
Inactive p53
Tissue type
Colorectal carcinoma
HCT116
HCT116-p53 K/O
Osteosarcoma
U2OS
SAOS-2
Table 2.1 The above matrix shows how four cell lines are organized based on tissue type
and p53 status. The HCT116 p53 K/O (hereafter referred to as simply “K/O”) was
generated by the lab of B. Vogelstein (Bunz et al., 1999). The SAOS-2 cell line is known
to have null p53 (ATCC, 2008).
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2. Identification of Putative p53 Binding Sites
The WRAP53α promoter sequence, which was originally isolated by Karmen Best
and described in Erlandson, Hucks, Budidi, Rapp, & Reisman (accepted for publication;
currently in revision) (Figure 2.1), was run on PROMO software, version 3.0.2, which was
developed by the Algorithmics and Genetics Group (ALGGEN), a branch of the
Algorithms, Bioinformatics, Complexity and Formal Methods (ALBCOM) research group
in the Computer Science department of the Universitat Politècnica de Catalunya (Farré et
al., 2003). Only human sites and human transcription factors were searched.

ctggaactggaatggcctagcccaaagctagataacaggtagattgtttttcccgacaaattatcaaacgacccatcattgcac
tctttcaaaatttcattctcagacgtaccattcttttttttttttctccgggaagatgagatatgctcattcttgaaagtgcctccgggct
tgccttctgcacacttctttccctccctgtctacgccatggtagcgtccgcctaggttgcaggcgacccggggggtggggcac
accattcaaagaaggggagggattgaggtttgcatcaaaacaaatacccctgcctttgcaaaggccataactaagtaatccag
aaaaagaaatgcaggcggagaatagcagcctccctctgccaagtaagaggaaccggcctaaaggacattttctctctctctc
ctcccctctcatcgggtgaatagtgagctgctccggcaaaaagaaaccggaaatgctgctgcaagaggcagaaatgtaaat
gtggagccaaacaataacagggctgccgggcctctcagattgcgacggtcctcctcggcctggcgggcaaacccctggttt
agcacttctcacttccacgactgacagccttcaattggattttctccatctagcggagccgggggctgcctggaaagatcgctc
caggaaggacaaaggtccggaagttgtgggaccttagcagcttgggctccccggatcacccccaaatgatcatttcggaatg
gagccccagttttcactaggatgccatgggctctaaaatatacagctatgagttctcaatgtttcgagatccaaaagtctcagac
ctcaatgctttgtgcatcttttatttcagggattccctacgcccagcaccgggtggatgtgcaaagaagtacgctttaggccggc
tcaaggttccccaaagctccactcctctgcctaggcgttcaactttgagttcggatggtcctaacatccccatcatctacaccca
ggtctcccaacaatgcaactcctatgatgatccctctagccaagcttccatcccactcacccccaaactcgctaagtccccact
gccccacccccagccccagcgattttcccgagctgaaaatacacggagccgagagcccgtgactcagagaggactcatca
agttcagtcaggagcttacccaatccagggaagcgtgtcaccgtcgtggaaagcacgctcccagcccgaacgcaaagtgtc
cccggagcccagcagctacctgctccctggacggtggctctagacttttgagaagctcaaaacttttagcgccagtcttgagc
acatgggaggggaaaaccccaatcccatcaacccctgcgaggctcctggcacaaagctggacagtcgccatgacaagtaa
gggcaagtaatccgcctgccggaggaagcaaaggaaatggagttggggaggagggtgcagagtcaggattctc
Figure 2.1. The WRAP53α promoter and first exon sequence is 1,487 nucleotides long.
The previously cloned WRAP53α promoter and first exon sequence, pictured here in the 5’
→ 3’ orientation, is 1,487 nucleotides in length. The first exon is indicated by red font. The
gene is located on chromosome 17p13.1 and is antiparallel from tumor suppressor p53.
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3. Site-Directed Mutagenesis
In order to determine the consequences of deleting each of the identified putative
p53 binding sites, specific targeted deletions were made in the WRAP53α promoter; Figure
2.2 provides a summary of how this strategy was employed.

Generation of
mutant promoters
with targeted
deletions

PCR amplification
of each site in
mutant and wildtype promoters (for
comparison)

Transformation
into bacteria and
transfection into
cell lines

Figure 2.2. Successful application of site-directed mutagenesis occurs in three distinct
stages. Mutant promoters were created with site-directed mutagenesis, each missing one
putative binding site. The sites were PCR-amplified in both wild-type and mutant
promoters to compare the length and ensure the mutation was correct before molecular
cloning and subsequent transfection into cell lines occurred.

3.1 Generation of mutant promoters
A mutant promoter missing one of each of the three putative p53 binding sites
identified by PROMO was designed using the NEBaseChanger software (New England
Biolabs) and generated using PCR (Figure 2.3). Primers were ordered from Life
Technologies and resuspended in water at a concentration of 50 pmol/µL (Table 2.2; Table
2.3) The PCR was run using a PTC-100 thermal cycler (MJ Research Inc.) (Table 2.4) and
the product was tested on a 3.5% agarose gel.
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A.

B.

C.

D.

Figure 2.3. Mutant promoters were designed with the NEBase Changer. (A) Although
the mutant promoter designed was through deletion only, the experimental design for all
types of mutations is shown. The designed primers were used for exponential amplification
via PCR, and the PCR product was isolated, enriched, and transformed into competent
Escherichia coli. (B) The design strategy for site-directed deletions is shown, wherein the
blue segment represents the deleted nucleotides, while the red arrow represents the origin
of a 3’ → 5’ PCR amplification to the left of the putative binding site and the black arrow
represents the origin of a 5’ → 3’ PCR amplification to the right of the putative binding
site. (C) The intermediate PCR product for site-directed mutagenesis is shown in linear
form. The black line represents the starting point for 5’ → 3’ generation, while the red line
represents the starting point for 3’ → 5’ generation. (D) The final product of site-directed
mutagenesis is shown in plasmid form, with the black line representing the 5’ origin
immediately following the deleted putative binding site and the red line representing the 3’
origin immediately preceding the deleted putative binding site. *Images taken from New
England Biolabs
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Table 2.2. Primers were designed to generate three mutant promoters missing one
putative p53 binding site each.
Site
Primer Sequence (5’ → 3’)
Sequence Deleted
F: ACAGGTAGATTGTTTTTCC
1

cccaaagctagata
R: CTAGGCCATTCCAGTTCCAG
F: TCTGCACACTTCTTTCCC

2

attcttgaaagtgcctccgggcttgcct
R: GAGCATATCTCATCTTCCC
F: TCCGCCTGCCGGAGGAAG

3

cgccatgacaagtaagggcaagtaa
R: ACTGTCCAGCTTTGTGCCAGG

Table 2.2. Each pair of primer sequences, shown in the 5’ → 3’ orientation, flank one of
three putative p53 binding sites within the WRAP53α promoter. Upon successful PCR
amplification, each primer pair resulted in the generation of one plasmid, missing its
putative p53 binding site, with the exception of site one, which retained 7 nucleotides at
the 5’ end, due to its proximity to the 5’ end of the promoter. F= forward primer sequence;
R = reverse primer sequence

Table 2.3. PCR reactions were set up to generate three mutant promoters.
Reaction
Volume
Final
Manufacturer
Component
Added
Concentration
Q5 Hot Start High-Fidelity
New England
Master Mix
12.5 µL
1X
Biolabs
2X
Primer (F)
Life Technologies
1.25 µL
0.25 pM
5 pmol/µL
Primer (R)
Life Technologies
1.25 µL
0.25 pM
5 pmol/µL
Template DNA
-1 µL
1-25 ng
1-25 ng/µL
Nuclease-Free Water
Promega Corporation
9 µL
-Table 2.3. Each of the plasmids missing one of three putative p53 binding sites was
amplified with PCR using the listed reaction conditions. The total volume was 25 µL. F=
forward primer; R = reverse primer. *Table based on reaction recommendations from New
England Biolabs
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Table 2.4. A thermal cycler was used to generate mutant promoters.
Step
Temperature
Time
Initial Denaturation
95°C
2 minutes

Elongation
30 Cycles

95°C
55°C
72°C

30 seconds
45 seconds
3 minutes

Final Extension
72°C
2 minutes
Hold
4°C
Indefinitely
Table 2.4. The thermal cycler conditions listed were used to generate mutant primers
missing one of each putative p53 binding site on the WRAP53α promoter. *Table based on
reaction recommendations from New England Biolabs

3.2 Kinase, ligase, & DpnI (KLD) reaction
Following successful PCR amplification of the mutant plasmids, the PCR products
were enriched using a KLD kit (New England Biolabs) which phosphorylates and ligates
linear DNA into a circular plasmid and removes bacterial template DNA (Table 2.5). The
KLD reaction product was incubated at room temperature for 5 minutes post-reaction and
then stored at -20°C.

Table 2.5. The kinase, ligase, and DpnI (KLD) reaction was used to enrich mutant
PCR products.
Volume
Final
Component
Manufacturer
Added
Concentration
PCR Product
-1 µL
-(mutant promoter)
KLD Reaction Buffer
New England Biolabs
5 µL
1X
2X
KLD Enzyme Mix
New England Biolabs
1 µL
1X
10X
Nuclease-Free Water
Promega Corporation
3 µL
-Table 2.5. Each of the mutant plasmids underwent enrichment in order to phosphorylate
and ligate the linear DNA and cut bacterial-derived DNA, which possesses a methyl group
at the DpnI site. The total volume was 10 µL. *Table based on reaction recommendations
from New England Biolabs
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3.3 Transformation
Five µL of KLD reaction product (New England Biolabs) were mixed with 50 µL
of competent E. coli (Bioline), thawed on ice, in a 10 mL polypropylene tube. The mixture
was further incubated on ice for ten minutes and then placed in a water bath at 42°C for
precisely 45 seconds. The polypropylene tube was returned to ice and 450 µL of super
optimal broth with catabolite repression (SOC) media (20 g Bacto tryptone, 5 g Bacto yeast
extract, 0.5 g NaCl, 20 mL of 250 mM KCl, 20 mL of 2M glucose, supplemented with 5
mL 2M MgCl2 per L, pH = 7.0) was added. The mixture was shaken at 37°C for 1 hour
and then plated at concentrations of 10% and 90% on Luria broth (LB) dishes (10 g Bacto
tryptone, 5 g Bacto yeast extract, 10 g NaCl per L) containing ampicillin (final
concentration = 100 µg/mL, Sigma-Aldrich). The plates were incubated overnight at 37°C.

3.4 Mini prep
Isolated colonies from the transformation were picked and transferred into 10 mL
polypropylene tubes containing 2 mL of LB media and 100 µg/mL ampicillin. For each
putative binding site deleted, 15-18 colonies were picked. The bacteria were shaken
overnight at 37°C.
The Epoch Life Science GenCatch Plasmid DNA Miniprep Kit was used to extract
and purify DNA. For each colony, 1 mL of plasmid-containing bacterial cells suspended
in LB media was transferred to an Eppendorf tube. The cells were centrifuged at 1,300
revolutions per minute (RPM) for 2 minutes, and the supernatant was removed. The pellets
were resuspended in 200 µL of VP1 buffer (Epoch Life Science) by scratching the tube
against a test tube rack. 250 µL of P2 buffer (Epoch Life Science) was added and the tube
was gently inverted several times. The mixture was incubated at room temperature for five
35

minutes. 350 µL of N3 buffer was added and gently mixed, then incubated on ice for 10
minutes. The mixture was then centrifuged for 10 minutes at 1,300 RPM, according to the
Epoch Life Science GenCatch Plasmid DNA Miniprep Kit instructions.
During centrifugation, GenCatch Plus columns were placed onto their
corresponding collection tubes (Epoch Life Science). Following centrifugation, the
supernatant was transferred to the GenCatch Plus columns and both the columns and tubes
were centrifuged for 1 minute at 5,000 RPM. The flow-through was discarded, and the
column was washed with 500 µL of PE buffer, then centrifuged for 1 minute at 9,000 RPM.
The flow-through was again discarded, and the column was centrifuged for 2 minutes at
13,000 RPM to remove residual ethanol. The columns were placed on their corresponding
Eppendorf tubes and 50 µL of nuclease-free water was added. The columns were incubated
at room temperature for 2 minutes and the DNA was eluted by centrifugation at 13,000
RPM for 30 seconds (Epoch Life Science). Each buffer used and its purpose is given in
Table 2.6.

Table 2.6. Mini prep buffers were used to isolate and purify DNA.
Buffer
Function
VP1 Buffer (MX1 Buffer)
Resuspension buffer with RNAse A
P2 Buffer (MX2 Buffer)
Lysis buffer
N3 Buffer (MX3 Buffer)
Neutralization buffer
PE Buffer (WN/WS Buffer)
Wash buffer
Nuclease-Free Water (EB Buffer)
Elution medium
Table 2.6. VP1, P2, N3, and PE Buffers were all used in mini prep DNA isolation and
purification. The buffer name in parentheses indicates what the product is now sold as.
Nuclease-free water was used for elution instead of the Elution Buffer. *Buffers sold as
part of the Epoch Life Science GenCatch Plasmid DNA Miniprep Kit
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3.5 Confirmation of successful deletion and isolation with 3.5% agarose gel
In order to confirm that site-directed mutagenesis and mini preparation were
successful, additional PCR was used to amplify and compare the putative binding site
region size for the wild-type promoter and each of the three mutants. Primers were ordered
from Life Technologies and resuspended at a concentration of 50 pmol/µL (Table 2.7). 50
µL PCR reactions were set up and run using a PTC-100 (MJ Research Inc.) (Table 2.8;
Table 2.9). The PCR products were run on a 3.5% agarose gel, which was poured by
slowly adding 3.5 g low-melting temperature agarose powder (Lonza) to a 500 mL
Erlenmeyer flask with 100 mL of 1X Tris-acetate-EDTA (TAE) (8 mM Tris, 4 mM glacial
acetic acid, 0.4 mM EDTA, pH = 8.0) while stirring. The mixture was allowed to stand for
15 minutes before being covered with cling wrap, which was pierced for ventilation. The
mixture was heated in a microwave for two minutes and monitored carefully. Upon boiling,
the flask was immediately removed from the microwave and swirled for twenty seconds.
This was repeated until all agarose powder was dissolved.
Once slightly cooled, 1 µL of 10 mg/mL ethidium bromide (Sigma-Aldrich) was
added, and the gel was poured and run at 100 volts (V) with 1X TAE and 5 µL of 0.1 µg/µL
GeneRuler 100 bp ladder (Thermo Fisher Scientific). All samples were mixed (9:1) with a
sample buffer mixture of 0.1% Bromo-phenol Blue (Thermo Fisher Scientific), 0.1%
Xylene cyanole FF (Sigma-Aldrich), and 50% glycerol, diluted in Tris-EDTA (TE) buffer
(10 mM Tris, 1 mM EDTA, pH = 8.0) prior to loading and brought to volume with
deionized water. The gel was viewed using a UV transilluminator (UVP, LLC.).
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For each site, the mini prep colony with the strongest band and least background
interference was selected for midi prep, and the polystyrene tube with plasmid-containing
bacterial cells in LB media was stored at 4°C until confirmation of successful midi-prep.

3.6 Midi prep
To grow the initial cell suspension, 100 mL of LB media (10 g Bacto tryptone, 5 g
Bacto yeast extract, 10 g NaCl per L) were added to a 500 mL Erlenmeyer flask and
supplemented with 50 µL of ampicillin (Sigma-Aldrich, final concentration = 50 µg/mL).
75 µL of plasmid-containing bacterial cells in LB media from each site’s respective “best
mini prep colony” (see 3.5) were added to the Erlenmeyer flasks, which were shaken
overnight at 37°C.
A GenCatch Plasmid DNA Midiprep Kit (Epoch Life Science) was used to isolate
purified plasmid DNA. The contents of the Erlenmeyer flasks were transferred to 250 mL
ultracentrifuge tubes (Nalgene). The tubes were centrifuged at 5,000 RPM for 15 minutes
using a J2-HS ultracentrifuge (Beckman Coulter).
During centrifugation, the GenCatch Midi columns were prepared. First, they were
shaken and equilibrated with 3 mL of 98% ethanol. The columns were allowed to empty,
and the flow-through was discarded. Next, 5 mL of VPN buffer (Epoch Life Science) were
added to the columns, and again, the flow-through was discarded after draining by gravity,
according to the Epoch Life Science GenCatch Plasmid DNA Midiprep Kit.
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Table 2.7. PCR products were generated using primers that flank each putative p53 binding site.
Site

Primer Sequence (5’ → 3’)
F: CTGGAACTGGAATGGCCTAG

1

R: GTCGGGAAAAACAATCTACC
F: CTCCGGGAAGATGAGATATG

2

R: CAGGGAGGGAAAGAAGTGTGC
F: CTCCTGGCACAAAGCTGGACAG

3

R: CTTTGCTTCCTCCGGCAGGCGG

Wild-Type PCR Product

Mutant PCR Product

ctggaactggaatggcctagcccaaagctagataacaggtagattgtttttcccgac
(57 bp)

ctggaactggaatggcctagacaggtagattgtttttcccgac
(43 bp)

ctccgggaagatgagatatgctcattcttgaaagtgcctccgggcttgccttctgcaca
cttctttccctccctg (75 bp)

ctccgggaagatgagatatgctcttctgcacacttctttccctc
cctg (48 bp)

cctggcacaaagctggacagtcgccatgacaagtaagggcaagtaatccgcctgcc
ggaggaagcaaag (69 bp)

cctggcacaaagctggacagtccgcctgtccggaggaagc
aaag (44 bp)
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Table 2.7. The primer sequences amplifying each putative p53 binding site are shown in the 5’ → 3’ orientation. Upon successful PCR,
each primer pair resulted in an amplified sequence very similar to each putative p53 binding site, with the exception of site one, wherein
the PCR product was slightly truncated at the 5’ end, relative to putative p53 binding site 1, due to its proximity to the 5’ end of the
promoter. These primers were used to select for colonies with the desired deletion by comparing relative lengths of each of the three
binding sites and choosing the one that did contain the deletion. F= forward primer sequence; R = reverse primer sequence. Red
sequences indicate the deleted nucleotides missing in the mutant PCR product

Table 2.8. 50 µL PCR reactions were set up using mini prep samples and the wild-type
WRAP53α promoter.
Reaction
Volume
Final
Manufacturer
Component
Added
Concentration
Nuclease-Free Water
Promega Corporation 32.5 µL
-GoTaq Buffer
Promega Corporation
10 µL
1X
5X
dNTP
Bio Basic Inc.
1 µL
200 µM
10 mM
DNA
-1 µL
1-25 ng
1-25 ng/µL
Primer (F)
Life Technologies
2.5 µL
0.25 pmol
5 pmol/µL
Primer (R)
Life Technologies
2.5 µL
0.25 pmol
5 pmol/µL
GoTaq G2 DNA Polymerase
Promega Corporation
0.5 µL
0.05 u
5u/µL
Table 2.8. Each of the three putative p53 binding sites was amplified—for both wild-type
and mutant promoters—with PCR using the listed reaction conditions and concentrations.
The total reaction volume was 50 µL. F= forward primer; R = reverse primer; dNTP =
deoxyribonucleotide triphosphate

Table 2.9. A thermal cycler was used to carry out PCR amplification of putative p53
binding sites.
Step
Temperature
Time
Initial Denaturation
95°C
2 minutes
95°C
55°C
74°C

Elongation
30 Cycles

30 seconds
1 minute
1 minute

Final Extension
74°C
5 minutes
Hold
4°C
Indefinitely
Table 2.9. The conditions listed above were used to generate control primers during PCR
amplification of each putative p53 binding site on the WRAP53α promoter and first exon.
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After centrifugation, the supernatant was removed with suction, and the cell pellets
were completely resuspended in 4 mL of VP1 buffer (Epoch Life Science). Following
resuspension by vortexing, 4 mL of VP2 buffer (Epoch Life Science) were added to the
ultracentrifuge tubes and the tubes were inverted to mix. The lysate was incubated at room
temperature for 5 minutes, and 4 mL of ice-cold VP3 buffer (Epoch Life Science) were
added. The lysate was gently mixed by inverting the tubes, which were then placed on ice
for 10 minutes (Epoch Life Science).
Post-incubation, the mixtures were centrifuged at 8,000 RPM for 15 minutes, and
the supernatant was applied to the equilibrated midi columns. The supernatant was allowed
to empty by gravity flow, and the flow-through was discarded. The column was washed
with 15 mL of VPN buffer (Epoch Life Science) and allowed to empty. Both the filtrate
and collection tubes were discarded, and the columns were placed over 30 mL glass test
tubes (Corex) and taped with laboratory film. Once secure, 5 mL of VPE Buffer (Epoch
Life Science) were added to the columns to elute the DNA.
The DNA was precipitated with 3.75 mL of isopropanol, then centrifuged at 8,000
RPM for 30 minutes, at 4°C. The supernatant was removed, and the DNA pellet was
washed with 5 mL of 70% ethanol and centrifuged at 6,000 RPM for 10 minutes. Again,
the supernatant was carefully removed and the DNA pellet was dried for 15 minutes, then
dissolved in 300 µL of TE, according to GenCatch Plasmid DNA Midiprep Kit
instructions. Buffers used in midi prep are given, in addition to their functions, in Table
2.10.
After isolation, the concentration of the DNA was checked using a NanoDrop
2000c spectrophotometer (Fisher Thermo Scientific) and the DNA was stored at -20°C. In
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order to confirm successful isolation of mutant plasmids, the DNA was checked using a
3.5% agarose gel (see 3.5), and with sequencing completed by Eton Bioscience (see 3.7)

Table 2.10. Midi prep buffers were used for large-scale DNA isolation and purification.
Buffer
Function
VP1 Buffer
Resuspension buffer with RNAse A
VP2 Buffer
Lysis buffer
VP3 Buffer
Neutralizing buffer
VPN Buffer
Wash buffer
VPE Buffer
Elution buffer
Isopropanol
Precipitating wash
70% Ethanol
Wash solution
Table 2.10. VP1, VP2, VP3, VPN, and VPE Buffers were all used for midi-prep DNA
isolation and purification, in addition to room-temperature isopropanol and 70% ethanol.
All alcohol was evaporated before the DNA was suspended in TE. *Buffers supplied
through the GenCatch Plasmid DNA Midiprep Kit (Epoch Life Science)

3.7 Sequencing
Sequencing of the uncut WRAP53α promoter and all three mutant derivatives were
completed by Eton Biosciences (Table 2.11).

4. Transfections and Reporter Assays
4.1 Preparation of plasmids for transfection
The WRAP53α promoter was cloned by Karmen Best as cited in Erlandson et al.
(accepted for publication; currently in revision) into a pGL3 luciferase reporter vector
(Promega) (Figure 2.4). For assays with p53 titrations, a pC53-C1N3 plasmid with wildtype p53 expression, first cloned by Arnold Levine in 1992 was used to transfect cell lines
with wild-type p53 (Figure 2.5).
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Table 2.11. All promoters were sequenced according to Eton Bioscience specifications.
Sample Concentration
Sample Size
Sequencing Primer
Sample Name
(ng/µL)
(bp)
(5’ → 3’)
WrapAlpha (1)
WrapAlpha (2)
Site 1
Site 2
Site 3

150
150
150
150
150

6,305
6,305
6,284
6,277
6,279

CTAGCAAAATAGGCTGTCCC
CATCAAGTTCAGTCAGGAGC
CTAGCAAAATAGGCTGTCCC
CTAGCAAAATAGGCTGTCCC
CATCAAGTTCAGTCAGGAGC

Primer Concentration
(nmol)
25
25
25
25
25

Table 2.11. The specifications used for all sequencing orders are listed above. Due to size limitations, the wild-type WRAP53α promoter
was sequenced in two separate reactions, shown here as WrapAlpha 1 and WrapAlpha 2. One sequencing primer was used for the first
half of the promoter, while an additional primer was used for the second half. Both the Site 1 and Site 2 deletions, which occur within
the first 200 nucleotides of the promoter, were compared with sequencing results from the WrapAlpha 1 sample in order to confirm
successful deletion, while the Site 3 deletion, which occurs within the last 200 nucleotides of the promoter/first exon sequence, were
compared with the sequencing results from the WrapAlpha 2 sample. *Table based on Eton Biosciences Inc. webpage order
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A Renilla luciferase pRL-null vector (Promega), which contains a known cryptic
promoter was used as an internal control in all transfections (Figure 2.6), and a BSSK
vector (Stratagene) was used to equalize the amount of DNA in each transfection (Figure
2.7).

Figure 2.4. The WRAP53α promoter and first exon were inserted into the pGL3 Firefly
luciferase reporter vector (by Promega). The inserted DNA was flanked by restriction
enzyme cut sites for KpnI and XhoI, neither of which are found in the promoter or first
exon sequence. The luc+ gene feature of the pGL3 vector codes for Firefly luciferase and
other features include ampicillin resistance. *Image taken from Promega
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Figure 2.5. The wild-type CMV p53 vector was used for experiments with p53
transfections. The pC53-C1N3 plasmid expresses wild-type human p53 cDNA but is only
partially genomic due to the presence of introns. In addition, the plasmid contains an origin
of replication, ampicillin and neomycin resistance, and a strong CMV promoter. *Figure
2.5 is an original image modeling a hand-drawn vector map created by Arnold Levine in
1992

4.2 Transfection preparation
Cells were grown to 80% confluency and split into 24-well plates (CytoOne) with
5x104 cells per 1 mL well. The cells were incubated overnight at 37°C before transfection.
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Figure 2.6. The pRL-null Renilla luciferase vector was used as a control. The pRL-null
Renilla luciferase vector is an internal control vector that has a known cryptic promoter. In
addition, the plasmid contains an origin of replication and ampicillin resistance. *Image
taken from Promega

4.3 Transfection
Three types of transfections were completed, each with specific reaction
conditions: baseline analysis (see 4.4), p53 titration (see 4.5), and DNA damage (see 4.6).
All transfections were performed twice in duplicate when cells reached 80% confluency
for four total trials. Following the addition of TransFast reagent (Promega, 0.4 mg
suspended in 400 µL of nuclease free water), the reaction tubes were vortexed well and
incubated at room temperature for ten minutes. The media was removed from the 24-well
plates and 195 µL of transfection mixture was added to adherent cells in each well. The
cells were incubated at 37°C for one hour, and then 1 mL of warm DMEM was added to
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each well. After 24 hours of incubation at 37°C, cells were either harvested or subjected to
DNA damaging reagents, depending on the type of experiment.

Figure 2.7. A BSSK vector was used to control the amount of transfected DNA in
titration experiments. The BSSK vector exists as a 2,958 bp plasmid and was transfected
to equalize the amount of total DNA in each transfection reaction. *Image taken from
Addgene Plasmid Repository and modified from Stratagene

4.4 Baseline analysis
To gauge the basal expression patterns of the WRAP53α promoter and the effects
of putative p53 binding site deletions, a baseline analysis was conducted. The amount of
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reporter DNA was increased and was equalized with the addition of the BSSK vector
(Table 2.12).

Table 2.12. Baseline analysis transfections were used to test each reporter DNA
promoter.
Amount Added for Desired Concentration
(µg/µL)
Component

Manufacturer

0.0 µg

0.1 µg

0.25 µg

0.5 µg

DMEM

--

385 µL

385 µL

385 µL

385 µL

Stratagene

10 µL

8 µL

5 µL

0 µL

--

0 µL

2 µL

5 µL

10 µL

Promega

2 µL

2 µL

2 µL

2 µL

Promega

3 µL

3 µL

3 µL

3 µL

BSSK
(0.1 µg/µL)
Reporter DNA
(0.1 µg/µL)
Renilla
Luciferase
(0.025 µg/µL)
TransFast
(1 µg/µL)

Total Volume = 400 µL
Table 2.12. In order to test promoter activity, the amount of reporter DNA transfected into
HCT116, U2OS, SAOS-2, and K/O cells was increased (0.0, 0.1, 0.25, and 0.5 µg/ mL).
The experiment was conducted in duplicates (195 µL added per well) and the wild-type
WRAP53α promoter, in addition to Site 1, 2, and 3 mutants, was used as reporter DNA.
The reaction compositions are presented.

4.5 p53 titration
To gauge the effects of increasing amounts of transfected p53, the amount of p53
vector was increased while the amount of reporter DNA (wild-type WRAP53α promoter
and Site 1, 2, and 3 mutants) was held constant (Table 2.13).
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Table 2.13. Transient transfections were used to examine the effects of exogenous
overexpression of p53 on each reporter DNA.
Amount Added for Desired p53
Concentration (µg/µL)
Component

Manufacturer

0.0 µg

0.1 µg

0.25 µg

0.5 µg

DMEM

--

379.8 µL

379.8 µL

379.8 µL

379.8 µL

Stratagene

10 µL

8 µL

5 µL

0 µL

--

0 µL

2 µL

5 µL

10 µL

--

4 µL

4 µL

4 µL

4 µL

Promega

2 µL

2 µL

2 µL

2 µL

Promega

4.2 µL

4.2 µL

4.2 µL

4.2 µL

BSSK
(0.1 µg/µL)
CMN p53
(0.1 µg/µL)
Reporter DNA
(0.1 µg/µL)
Renilla
Luciferase
(0.025 µg/µL)
TransFast
(1 µg/µL)

Total Volume = 400 µL
Table 2.13. In order to test the effects of increasing amounts of transfected p53 (in plasmid
form), the amount of p53 transfected into HCT116, U2OS, SAOS-2, and K/O cells was
increased. The experiment was conducted in duplicates (195 µL added per well) and the
wild-type WRAP53α promoter, in addition to Site 1, 2, and 3 mutants, was used as reporter
DNA. The reaction compositions are presented.

4.6 DNA damage analysis
24 hours post-transfection with 0.4 µg of reporter DNA/well, cells were treated
with the following DNA damaging drugs (Sigma-Aldrich) at the specified concentrations
and incubated for 24 hours at 37°C before harvesting unless otherwise noted: actinomycin
D (10 nM), camptothecin (15 µM), cisplatin (35 µM), doxorubicin (1 µM) and etoposide
(10 µM). In DNA damage experiments, a BAX promoter/luc construct and p21
promoter/luc construct were used as positive controls, since p53 is known to bind to both
promoters in response to DNA damage.
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4.7 Cell harvest
Unless otherwise specified, cells were harvested 24 hours after transfection or
treatment with DNA damaging agents. The media was removed from the 24-well plates,
and the cells were washed once with 0.5 mL of 1X phosphate buffer saline (PBS) (SigmaAldrich). 5X Passive Lysis Buffer (Promega) was diluted to 1X with dH2O and cells were
shaken for 20 minutes at room temperature in 0.1 mL of the dilution. Extracts were stored
at -20°C until ready for a protein measurement (Bradford) assay (see 4.8).

4.8 Protein measurement (Bradford) assay
2 µL of cellular extract from each harvest was added to a mixture of Protein Assay
Dye (Bio-Rad) diluted 1:5 with water (total volume = 1.002 mL). Blanking solutions were
created from diluted Protein Assay Dye (Bio-Rad) without any extract (total volume = 1.00
mL) and the absorbance of each sample was read at 595 nanometers (nm) using a UV-1700
spectrophotometer (PharmaSpec). Protein content was normalized using a standardized
BSA curve. The amount of extract (in µL) required to yield 5 µg of protein was recorded
and used as the sample input amount for the luciferase assay (see 4.9).

4.9 Luciferase assay
To measure promoter activity, a luminometer reading was gathered using the DualLuciferase Reporter Assay System (Promega). The appropriate amount of cellular extract
(see 4.8) was added to 100 µL of Luciferase Assay Reagent (Luciferase Assay Buffer II
[10 mL] and Luciferase Assay Substrate (lyophilized, 1 vial per 10 mL], Promega,) and a
Firefly luciferase reading was taken using a Femtomaster FB 12 luminometer (Zylux
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Corporation). Then, 100 µL of Stop & Glo mixture (2 µL of 50X Stop & Glo substrate per
sample, mixed with 100 µL of Stop & Glo buffer per sample) were added to the mixture
for a Renilla luciferase reading. All numbers were normalized to Renilla values.

5. Western Blot Analysis
5.1 Tissue culture
Tissue culture was carried out as described in sections 1 and 4.6. For endogenous
studies wherein no transfection occurred, in order to harvest the cells, the media was
suctioned off and the cells were washed once with 10 mL of 1X PBS, which was
subsequently removed. Cells were scraped in 1 mL of 1X PBS and transferred to a
microcentrifuge tube, which was centrifuged for 2 minutes at 10,500 RPM. The supernatant
was removed and the pellet was resuspended in 100 µL of 1X Passive Lysis Buffer. Prior
to a protein measurement assay (see 4.8), harvests were sonicated using a VirTis Virsonic
50 sonicator at 80% output in five 2-second pulses. Following sonication, sheared samples
were centrifuged for 2 minutes at 10,500 RPM and the supernatant was transferred to a
fresh 1.7 mL microcentrifuge tube. Samples were stored at -20°C.

5.2 Running the polyacrylamide gel
The lower gel was poured while stirring and consisted of 1.7 mL of deionized water,
1.25 mL of 4X buffer (1.5M Tris-HCl, 18.15 g/100 mL, pH = 8.8; 0.4% sodium dodecyl
sulfate [SDS]), 2.0 mL of 30% acrylamide (29:1 acrylamide:bis per 100 mL), 5 µL of 99%
tetramethylethylenediamine (TEMED) (Sigma-Aldrich), and 25 µL of 10% ammonium
persulfate (APS) (Sigma-Aldrich, 10% weight by volume). The lower gel was allowed to
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stir for 20 seconds and transferred to the plates (Bio-Rad) using a Pasteur pipette, and the
top of the gel was leveled by adding several drops of N-butanol. The lower gel was allowed
to polymerize for twenty minutes, and the N-butanol was removed by rinsing with
deionized water.
The upper gel was also poured while stirring and consisted of 3.1 mL of deionized
water, 1.25 mL of 4X buffer (0.5M Tris-HCl, 6 g/100 mL, pH = 6.8; 0.4% SDS), 0.65 mL
of 30% 30% acrylamide (29:1 acrylamide:bis per 100 mL), 5 µL of 99% TEMED (SigmaAldrich), and 25 µL of 10% APS (Sigma-Aldrich, 10% weight by volume). The upper gel
was allowed to mix for 20 seconds and was then added to the plates (Bio-Rad) using a
Pasteur pipette. A comb was inserted and the upper gel was allowed to polymerize for 20
minutes.
The samples were prepared based on results from Bradford assays (see 4.8) and
deionized water was used to bring small samples up to a 10 µL minimum threshold. 2X
Laemmli sample buffer (Bio-Rad, supplemented with 5% 2-mercaptoethanol) was added
in a 1:1 ratio based on sample or sample/water volumes. All samples were boiled at 100°C
for sixty seconds to denature prior to loading.
After the upper gel was fully polymerized, the comb was removed and the wells
were rinsed with deionized water. The reservoir chamber (Bio-Rad) was covered with 1X
SDS buffer (3 g Tris-HCl, 14.4 g glycine, 1 g SDS/L) and 5 µL of Precision Plus Protein
Kaleidoscope ladder (Bio-Rad) were loaded. The denatured samples were loaded and run
at 100 V until samples passed through the stacking buffer. The samples were run at 200 V
until the dye passed through the lower buffer and into the chamber.
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5.3 Running the transfer gel
Prior to running the transfer gel, the transfer gel cassette (Bio-Rad), two sponges,
and two pieces of filter paper were soaked in 1X protein transfer buffer (3.03 g Tris, 14.4
g glycine, 20% methanol by volume). A piece of nitrocellulose paper (GE Healthcare Life
Sciences) was carefully cut and rinsed in deionized water, then soaked in 1X protein
transfer buffer. The protein gel was removed from the reservoir chamber and rinsed in
deionized water. The upper buffer was removed with a razor and the remaining lower
buffer gel was soaked in 1X protein transfer buffer. The blotting cassette was set up in the
following order, from front to back: cassette, sponge, filter paper, gel, nitrocellulose, filter
paper, sponge, cassette. The cassette was closed and placed into the reservoir chamber,
which was filled with 1X protein transfer buffer. A stir bar was added to the chamber, along
with an ice pack, and the whole reservoir chamber was run in an ice bucket, with stirring,
for 1.5 hours at 100 V.

5.4 Blocking
After gel transfer, the cassette was carefully unpeeled and the nitrocellulose was
placed in 1X tris-buffered saline/Tween-20 mixture (TBST) (1M Tris, pH = 8, 5M NaCl,
Tween-20, 0.05% by volume) and swirled. The TBST was discarded and replaced with 2%
blocking mixture (Carnation Instant Dry Milk, 20 g/L). The nitrocellulose was covered
with plastic film and incubated overnight at 4°C.

5.5 Incubation with first and second antibodies
The 2% milk mixture was poured off and the nitrocellulose was rinsed with TBST.
The first antibody mixture (p53 [Ab-6] monoclonal antibody, 100µg/mL, [Oncogene], and
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p53 [Ab-1] monoclonal mouse immunoglobulin G [IgG], 100 µg/mL, [Oncogene]) was
poured over the nitrocellulose in a thin layer (Table 2.14). The mixture was shaken for one
hour, then removed, and the nitrocellulose was rinsed three times with TBST. The
nitrocellulose was shaken for 30 minutes in TBST, which was replaced every ten minutes.
After the interval shaking, the TBST was removed, and 10 mL of the second
antibody mixture (anti-Mouse IgG peroxidase antibody produced in rabbit, Sigma-Aldrich)
was poured over the nitrocellulose in a thin layer (Table 2.15). The nitrocellulose was
incubated in the second antibody, with shaking, for one hour. The second antibody was
removed and the nitrocellulose was rinsed four times with TBST. The nitrocellulose was
shaken for 30 minutes in TBST, which was replaced every ten minutes.

Table 2.14. The p53 primary antibody was composed of TBST, sodium azide, two types
of monoclonal antibodies, and bovine serum albumin (BSA).
Amount
Final
Component
Manufacturer
Added
Concentration
TBST
-9.5 mL
0.94X
(1X)
Sodium azide
Sigma-Aldrich
50 µL
0.05%
(10%)
p53 [Ab-6] monoclonal antibody
Oncogene
5 µL
0.05 µg
(100 µg/mL)
p53 [Ab-1] monoclonal mouse IgG
Oncogene
5 µL
0.05 µg
(100 µg/mL)
Bovine serum albumin
Sigma-Aldrich
500 µL
0.5%
(10% weight by volume)
Table 2.14. The amounts of each component for the p53 primary antibody are listed. The
final volume of the primary antibody was 10.06 mL.
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Table 2.15. The anti-mouse secondary antibody was composed of TBST, anti-mouse
antibody, and BSA.
Amount
Final
Component
Manufacturer
Added Concentration
TBST
-9.5 mL
0.95X
(1X)
Anti-mouse IgG peroxidase antibody
Produced in rabbit
Sigma-Aldrich
1 µL
1 – 2 µg
(10 - 20 mg/ml)
BSA
Sigma-Aldrich
500 µL
0.5%
(10% weight by volume)
Table 2.15. The relative amounts of each component used for the p53 secondary antibody
are listed. The final volume of the secondary antibody was 10.001 mL.
5.6 Detection
Prior to detection, the nitrocellulose was rinsed in TBST three additional times. An
ImageQuant LAS 4000 biomolecular imager (GE Healthcare Life Sciences) was used to
view results. The nitrocellulose was removed from the TBST using tweezers and blotted
on filter paper, then covered in a 1:1 mixture of WesternSure PREMIUM Luminol
Enhancer Solution and Stable Peroxide Solution (LI-COR Biosciences). The nitrocellulose
was incubated in the mixture for 5 minutes, then again blotted on filter paper using tweezers
and loaded into the imager on cling wrap according to optimal settings (Table 2.16).

Table 2.16. Optimal exposure settings were used for chemiluminescent detection of
proteins.
Element
Setting
Exposure type
Precision
Exposure time
Auto
Resolution
Standard
Digitization of image
On
Method/Tray position
1
Method
Chemilumination
Table 2.16. All samples were viewed using the ImageQuant LAS 4000 biomolecular
imager (GE Healthcare Life Sciences). The above settings were used for each Western blot.
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5.7 Control blots
Following detection of p53, a β-actin control blot was performed on each
nitrocellulose (see 5.5 and 5.6). Tables 2.17 and 2.18 indicate the primary and secondary
antibody compositions.

Table 2.17. The β-actin primary antibody was composed of TBST, sodium azide, a
monoclonal goat antibody, and BSA.
Amount
Final
Component
Manufacturer
Added
Concentration
TBST
-9.5 mL
0.94X
(1X)
Sodium azide
Sigma-Aldrich
50 µL
0.05%
(10%)
Actin (I-19) goat polyclonal IgG
Santa Cruz
10 µL
0.2 µg
(200 µg/mL)
Biotechnology
BSA
Sigma-Aldrich
500 µL
0.5%
(10% weight by volume)
Table 2.17. The relative amounts of each component for the β-actin primary antibody are
listed above. The final volume of the first antibody was 10.06 mL.

Table 2.18. The anti-goat secondary antibody was composed of TBST, anti-goat
antibody, and BSA.
Component

Manufacturer

Amount
Added

Final
Concentration

TBST
-9.5 mL
0.95X
(1X)
Donkey anti-goat IgG-HRP
Santa Cruz
1 µL
0.04 µg
(400 µg/mL)
Biotechnology
BSA
Sigma-Aldrich
500 µL
0.5%
(10% weight by volume)
Table 2.18. The relative amounts of each component for the β-actin secondary antibody
are listed above. The final volume of the secondary antibody was 10.001 mL. IgG-HRP =
immunoglobulin G-horseradish peroxidase
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6. Chromatin Immunoprecipitation (ChIP)
ChIP was carried out based on recommendations set forth in the ChIP-IT Express
kit by Active Motif.

6.1 Tissue culture
U2OS cells were grown to approximately 75% confluency in three 15 cm plates
(CytoOne) in 20 mL of DMEM with supplements (see Section 1: Tissue Culture) per plate.
The final cell count per plate prior to formaldehyde fixation was around 1.5 x 107.

6.2 Cross-linking
Prior to beginning the cross-linking step, the 10X glycine buffer (Active Motif) was
thawed at room temperature, and the Fixation solution was prepared by adding 0.54 mL of
37% formaldehyde (Fisher Chemical) with 20 mL of room temperature growth media (no
supplements) per plate. The Fixation solution was mixed thoroughly and kept at room
temperature. The media was suctioned off each 15 cm plate, and 20 mL of Fixation solution
was added to each plate in 10 mL increments. The plates were rocked until covered with
the Fixation solution and incubated on a shaking platform at room temperature for 10
minutes. During this incubation, a 15 mL conical tube was placed on ice to chill and the
following solutions were prepared:
a) 24.33 mL of 1X PBS per plate (ice-cold)
b) Glycine Stop-Fix solution: 1 mL of 10X glycine buffer (Active Motif) + 9 mL 1X
PBS per plate (left at room temperature)
c) Cell Scraping solution: 2 mL of 1X PBS per plate (ice-cold)
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After 10 minutes, the Fixation solution was suctioned off, and 10 mL of ice-cold 1X
PBS was added to each plate. The plates were rocked for 5 seconds, and the PBS was
suctioned off. Next, 10 mL of Glycine Stop-Fix solution (b) was added to each plate. The
plates were again rocked until covered and then allowed to incubate for 5 minutes at room
temperature with shaking.
Following this incubation, the Glycine Stop-Fix solution was suctioned off, and the
plate was again washed with 10 mL of ice-cold 1X PBS. The cells were rocked for 5
seconds, and the PBS was suctioned off. Twelve μL of 100 mM phenylmethylsulfonyl
fluoride (PMSF) (Active Motif) per plate was added to the Cell Scraping solution, and the
mixture was added to the cells.
Each plate was scraped thoroughly with a rubber policeman, with every effort being
made to maximize the number of cells collected. The scraped cells were then transferred
to a conical 15 mL tube and centrifuged at 4°C for 10 minutes at 2,500 RPM. With the 15
mL conical tube on ice, the supernatant was suctioned off, and the pellet was either used
immediately or stored at -80°C by adding1 μL of protease inhibitor cocktail (PIC) (Active
Motif) and 1 μL of 100 mM PMSF (Active Motif) to the cell pellet.

6.3 Douncing and shearing
If frozen, the cell pellet was thawed on ice and resuspended in its residual
supernatant prior to beginning. Next, the pellet was resuspended in 1 mL of ice-cold 1X
Lysis Buffer (Active Motif), supplemented with 5 μL of PIC (Active Motif) and 5 μL of
100 mM PMSF (Active Motif). The suspension was incubated on ice for 30 minutes.
During this incubation, a 2 mL dounce homogenizer (Wheaton Industries) was also chilled
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on ice. Following the half-hour incubation, a Pasteur pipette was used to transfer the lysate
to the dounce homogenizer. The lysate was dounced on ice for 10 strokes to isolate the
nuclei. The suspension was transferred to a 1.7 mL microcentrifuge tube and spun at 4°C
for 10 minutes at 5,000 RPM in order to pellet the nuclei.
The supernatant was carefully removed and discarded. The pellet was resuspended
in 1 mL of Shearing Buffer (Active Motif), supplemented with 5 μL of Active Motif PIC
and 5 μL of Active Motif 100 mM PMSF. The pellet was micropipetted up and down in
order to break up any clumps.
The chromatin was then sheared using the sonication program SonoLab (Covaris).
Shearing occurred in three-minute increments and was confirmed on a gel between each
interval until the sample was sufficiently sheared (see 6.4). The chromatin was centrifuged
at 4°C for 10 minutes at 15,000 RPM. The supernatant was transferred to a fresh
microcentrifuge tube and stored at -80°C until shearing efficiency could be confirmed (see
6.4). A 50 μL aliquot was transferred to another Eppendorf for this confirmation and was
either used immediately or stored at -80°C.

6.4 Confirming shearing efficiency
The 50 μL aliquot was allowed to completely thaw out on ice, and 150 μL of dH2O,
then 10 μL of 5 M NaCl (Active Motif) was added to the sample. The sample was
transferred to a 200 μL PCR tube (USA Scientific) and heated at 65°C overnight in a PCT100 thermocycler (MJ Research, Inc.) to reverse cross-links.
The sample was transferred to a 1.7 mL microcentrifuge tube and 1 μL of RNase A
(10 μg/μL) (Active Motif) was added. The sample was incubated on a heating block for 15
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minutes at 37°C. Ten μL of Proteinase K (0.5 μg/μL) (Active Motif) was added and the
sample was incubated for 90 minutes at 42°C in a water bath (EquaTherm).
The sample was mixed with 2.5 μL of a sample buffer mixture of 0.1% Bromophenol Blue (Thermo Fisher Scientific), 0.1% Xylene cyanole FF (Sigma-Aldrich), and
50% glycerol, diluted in TE buffer (10 mM Tris, 1 mM EDTA, pH = 8.0), and 10 μL of
this mixture was run on a 1X TAE gel at 100 V. The gel was post-stained by rocking at
room temperature for 30 minutes in 1X TAE supplemented with 50 μL of 10 mg/mL EtBr
(Sigma-Aldrich) and viewed with a UV transilluminator (UVP, Inc.). Optimal shearing
appeared as a 200 – 1500 bp banding pattern.
In the event of further shearing to achieve the desired banding pattern, 50 μL of
Shearing Buffer (Active Motif) was added to the stored chromatin (see 6.3) to bring the
sample volume back up to precisely 1 mL.

6.5 Immunoprecipitation (IP)
Once the shearing efficiency confirmation indicated that the chromatin was
sufficiently sheared, the supernatant (from 6.3) was completely thawed out on ice. The IP
reactions were set up on ice in siliconized 1.7 mL microcentrifuge tubes, while taking great
care to add the antibody last and to vortex the magnetic beads well prior to adding them
(Table 2.19).
The tubes were capped and incubated on an end-to-end rotator (Lab Industries, Inc.)
at 4°C overnight. Additionally, 10 μL of sheared chromatin were transferred to a fresh
Eppendorf tube and stored separately from the remainder of the chromatin at -80°C, to be
used as an input control.
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Table 2.19. Immunoprecipitations were set up as 100 μL reactions.
Antibody Used
p53
RNA Pol Serum

No
AB
25 μL
10 μL
40 μL
1 μL
24 μL
0 μL

Protein G Magnetic Beads (Active Motif)
25 μL
25 μL
25 μL
ChIP Buffer 1 (Active Motif)
10 μL
10 μL
10 μL
Sheared chromatin
40 μL
40 μL
40 μL
PIC (Active Motif)
1 μL
1 μL
1 μL
dH2O
19 μL
14 μL
23 μL
Antibody*
5 μL
10 μL
1 μL
Total Volume
100 μL
Table 2.19. The listed conditions were used for immunoprecipitation of four samples.
*Antibodies used included: a ChIP-certified p53 mouse monoclonal antibody (DO-1) (200
μg/0.1 mL) (Santa Cruz Biotechnology); a positive control RNA Polymerase II mouse
IgG1 antibody (0.2 mg/mL) (Active Motif); and a negative control IgG serum (Active
Motif). An additional negative control consisted of no antibody at all and was brought to
volume with dH2O. RNA Pol = RNA Polymerase II; No AB = no antibody

6.6 Washing the magnetic beads
Following an overnight incubation, the siliconized Eppendorf tubes were briefly
(~3 seconds at 5,000 RPM) centrifuged to remove liquid from the cap, without pelleting
the magnetic beads. The tubes were placed on a magnetic stand (DYNAL) to pellet the
beads to the side. The supernatant was removed and the beads fully resuspended in 800 μL
of ChIP Buffer 1 (Active Motif). Each sample was washed separately to prevent drying
out, and immediately upon resuspending the beads, the tube was placed on an end-to-end
rotator (Lab Industries, Inc.) at room temperature. Once each sample had rotated for at least
one minute, the samples were centrifuged briefly, as before, and again placed on the
magnetic stand (DYNAL). The beads were washed two additional times with ChIP Buffer
2 (Active Motif). After the final wash, as much supernatant as possible was removed from
the Eppendorf tube without disturbing the beads.
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6.7 Elution and cross-link reversal
Immediately after the final wash, the beads were resuspended in 50 μL of Elution
buffer AM2 (Active Motif). Each tube was incubated at room temperature on an end-toend rotator (Lab Industries, Inc.) for fifteen minutes. The samples were centrifuged briefly
(see 6.6) to collect liquid from the cap, and 50 μL of Reverse Cross Link buffer (Active
Motif) were added. The solution was mixed by pipetting up and down thoroughly. The
tubes were placed on the magnetic stand (DYNAL) to pellet the beads to the side, and the
supernatant was transferred to a PCR tube (USA Scientific).
To prepare the input sample, the 10 μL of chromatin (see 6.5) were also transferred
to a PCR tube (USA Scientific), and 88 μL of ChIP Buffer 2 (Active Motif) and 2 μL of 5
M NaCl (Active Motif) were added to the same tube and pipetted up and down. All five of
the samples—including the input—were incubated in a PTC-100 thermal cycler (MJ
Research Inc.) for 15 minutes at 95°C.
Following this incubation, the samples were returned to room temperature. 2 μL of
Proteinase K (0.5 μg/μL) (Active Motif) were added to each sample, which was then mixed
well, transferred to a fresh Eppendorf, and incubated at 37 °C for an hour. Fifteen minutes
in, the Proteinase K Stop solution (Active Motif) was allowed to thaw at room temperature
for forty-five minutes. The samples were brought back to room temperature, and 2 μL of
room temperature Proteinase K Stop solution (Active Motif) were added to each sample
and mixed with pipetting up and down. The sample was then frozen at -20°C until ready
for PCR.
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6.8 PCR & gel electrophoresis
In order to confirm whether or not the DNA sequences pulled down by ChIP
corresponded to the putative p53 binding sites, sequence-specific primers were used to
attempt to amplify known sequences that were suspected of being in the eluate; the primers
for Sites 1, 2, and 3 corresponded to the confirmations done during the mini prep stage
(Table 2.20). Reaction conditions are shown in Table 2.21. Thermal cycler conditions were
optimized to 33 cycles (Table 2.22).
The PCR product was mixed with 5 μL of a sample buffer mixture of 0.1% Bromophenol Blue (Thermo Fisher Scientific), 0.1% Xylene cyanole FF (Sigma-Aldrich), and
50% glycerol, diluted in TE buffer (10 mM Tris, 1 mM EDTA, pH = 8.0) prior to loading.
Forty μL of stained sample were loaded onto a 1% TAE gel, pre-stained with EtBr (SigmaAldrich), and run at 100 V alongside 5 µL of 0.1 µg/µL GeneRuler 100 bp ladder (Thermo
Fisher Scientific). The gel was viewed using a ultraviolet (UV) transilluminator (UVP,
LLC.).

6.9 Quantification
Gels were quantified using ImageJ. Once the bands were aligned at 180°, the image
was converted to an 8-bit black and white file, and the LUT was inverted. The Rectangle
tool was used to select the region of interest, excluding the ladder. The gel lanes were
plotted, and the Line tool was used to isolate each peak. The Wand tool was used to assign
each peak an area value, and the peaks were labeled with their percentages. The percentages
were calculated relative to the No Antibody lane in order to determine fold-change in pixel
intensity between No Antibody and p53 samples.
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Table 2.20. Sequence-specific primers were used to test if putative p53 binding sites
could be amplified from immunoprecipitated samples.
Amplification Region
Primer Sequence (5’ → 3’)
F: CTGGAACTGGAATGGCCTAG
Site 1

R: GTCGGGAAAAACAATCTACC
F: CTCCGGGAAGATGAGATATG

Site 2

R: CAGGGAGGGAAAGAAGTGTGC
F: CTCCTGGCACAAAGCTGGACAG

Site 3

R: CTTTGCTTCCTCCGGCAGGCGG
F: GTGGCTCTGATTGGCTTTCTG

P21

R: CTGAAAACAGGCAGCCCAAG

Table 2.20. The listed primers were used on the immunoprecipitated samples to determine
whether putative binding sites could be PCR-amplified. p21 was used as a positive control,
since p53 is known to bind to its promoter. A GAPDH primer mixture (Active Motif) was
also used on the RNA Polymerase II samples, as a positive control; the sequence of the
primers is unknown. F= forward primer sequence; R = reverse primer sequence

Table 2.21. PCR was used to amplify potential p53 binding sites in ChIP final
products.
Reaction
Volume
Final
Manufacturer
Component
Added
Concentration
Nuclease-Free Water
Promega Corporation
23.5 µL
-GoTaq Buffer
Promega Corporation
10 µL
1X
5X
dNTPs
Bio Basic Inc.
1 µL
200 µM
10 mM
Primer (F)
Life Technologies
2.5 µL
0.25 pM
5 pmol/µL
Primer (R)
Life Technologies
2.5 µL
0.25 pM
5 pmol/µL
GoTaq G2 DNA Polymerase
Promega Corporation
0.5 µL
0.05 u/µL
5 u/µL
ChIP Product
-10 µL
-Table 2.21. The listed reaction conditions were used to PCR amplify putative p53 binding
sites using the p53, RNA Pol II, serum, and no antibody ChIP products. The total volume
was 50 µL. For the RNA Pol II sample, a GAPDH mixture was used, instead of individual
F and R primers; therefore, 24.5 µL of nuclease-free water were used and 4 µL of the
GAPDH primer mix was used, instead of the values shown. F= forward primer; R =
reverse primer
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Table 2.22. Thermal cycler conditions were optimized to amplify regions of interest
within the ChIP product.
Step
Temperature
Time
Initial Denaturation
95°C
2 minutes

Elongation
33 Cycles

95°C
55°C
74°C

30 seconds
1 minute
1 minute

Final Extension
74°C
5 minutes
Hold
4°C
Indefinitely
Table 2.22. The conditions listed above were used to amplify regions of interest designated
by Site 1, 2, and 3 primers, GAPDH primers, and p21 primers for ChIP products p53, RNA
Pol II, serum, and No Antibody.
8. Data Analysis
Microsoft Excel and SAS Studio were used for data analysis and visualization.
ImageJ was used for quantification of gels following PCR for the ChIP assay only. The
Wilcoxon rank sum non-parametric alternative to the t-test was used to test for differences
between treatment group medians, as the sample size was not large enough to assume
normality.
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CHAPTER III
RESULTS

The WRAP53α gene is induced in response to DNA damage
Previous studies have shown that WRAP53α is induced in response to cisplatinmediated DNA damage, resulting in an increased production of mRNA (J. Yuan et al.,
2011). In a number of preliminary experiments, we corroborated this finding and further
characterized this induction. Using qPCR, we quantified gene expression at different
timepoints in U2OS cells and found a 2-fold increase in WRAP53α mRNA production 24
hours post-treatment with 35 μM cisplatin and an 8-fold increase 36 hours post-treatment
(Figure 3.1A). Similar experiments with 10 nM actinomycin D indicated an 11-fold
increase 18 hours post-treatment, which was sustained as an 8-fold increase 36 hours posttreatment. (Figure 3.1B). Identical experiments using other cell lines showed that, in
HCT116 cells, WRAP53α transcript levels increased 4-fold 24 hours post-treatment with
10 nM actinomycin D, while in RKO cells (a different colon carcinoma with wild-type
p53), there was no increase in response to DNA damage (data not shown).
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Figure 3.1. The WRAP53α gene is induced in response to DNA damage in U2OS cells.
(A) WRAP53α mRNA production in response to 35 μM cisplatin treatment was assayed in
U2OS cells. RNA was harvested at 0, 12, 24, and 36 hours post-DNA damage, then
subjected to qPCR analysis. (B) The fold change in WRAP53α expression was measured
in U2OS cells treated with 10 nM actinomycin D. Cells were treated and harvested at 0,
18, and 36 hours post-treatment. The RNA was purified and subjected to qPCR analysis.
Fold change in expression was calculated relative to expression at the time of treatment.
*Figures are based on or reprinted from Erlandson et al. (accepted for publication;
currently in revision)

The WRAP53α promoter is induced in response to DNA damage
In order to determine whether elevated levels of WRAP53α mRNA were due to
increased transcription in response to DNA damage, the WRAP53α promoter was cloned
into a luciferase reporter vector and tested in transient transfection assays. A cohort of
different DNA damaging drugs were used, including 10 nM actinomycin D, 15 µM
camptothecin, 35 μM cisplatin, 1 µM doxorubicin, and 10 µM etoposide. These transient
transfections in U2OS cells indicate that elevated promoter activity does indeed occur as a
response to DNA damage, but that the degree of heightened activity is drug-dependent
(actinomycin D= 2-fold; camptothecin = 3-fold; cisplatin = 2-fold; doxorubicin = 6-fold;
etoposide = 4-fold) (Figure 3.2).
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Figure 3.2. The WRAP53α promoter is induced in response to DNA damage. Transient
transfections in U2OS cells using a cloned WRAP53α promoter-luciferase reporter vector
revealed elevated transcription following a 24-hour incubation with 10 nM actinomycin D,
15 µM camptothecin, 35 μM cisplatin, 1 µM doxorubicin, and 10 µM etoposide. Fold
change in expression was calculated relative to a control group which was not treated with
any DNA damaging drugs but was transiently transfected with the WRAP53α promoter.
*Figure reprinted from Erlandson et al. (accepted for publication; currently in revision)

p53 was identified as a putative binding factor of the WRAP53α promoter
In order to identify which transcription factors could be responsible for
upregulating WRAP53α in response to DNA damage, the cloned promoter/first exon
sequence was run in the ALGGEN group’s PROMO software, which uses sequencespecific bioinformatic recognition to detect transcription factors that could, in theory, bind.
Sixty-six possible transcription factors, including p53, were identified by the software as
potentially being able to bind to the WRAP53α promoter/first exon sequence (Farré et al.,
2003) (Table 3.1). Due to the functional and geographic relationship between p53 and
WRAP53α (Mahmoudi et al., 2011), we decided to pursue a potential p53/WRAP53α
interaction as a mode of transcriptional regulation.
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Three putative p53 binding sites were identified within our WRAP53α cloned sequence
According to the PROMO software (Farré et al., 2003), p53 had the ability to
theoretically bind to 17 different sites throughout the cloned sequence; however, this
number was ultimately reduced based on the fact that the software did not recognize that
p53 must bind as a tetramer, requiring two separate half-sites separated by 0-13 bp, as
established by p53 literature (Brynczka, Labhart, & Merrick, 2007). A perfect consensus
sequence was determined to consist of two half-sites, A and B, each bearing the sequence
C(A/T)(A/T)G, separated by 0-13 bp. Furthermore, each half-site was found to be preceded
by three purines and followed by three pyrimidines (Brynczka et al., 2007; Figure 3.3).
Each putative binding site was compared to the established consensus sequence and
its mismatches were analyzed based on its fidelity to each separate criterion. Sequences
ggcctagcccaaagctagata (site 1) and attcttgaaagtgcctccgggcttgcct (site 2) were selected for
further analysis, as they showed the least degree of deviation from consensus. Additionally,
cgccatgacaagtaagggcaagtaa (site 4) and tgacaagtaagggcaagtaa (site 5), which overlap as
three distinct half-sites, were further analyzed as one putative binding site (hereafter
referred to as site 3). Sequence cgccatggtagcgtccgcctaggtt was excluded from further
analysis, as it had the largest degree of deviation from consensus (Table 3.2).

p53 is induced in response to doxorubicin- and cisplatin-mediated DNA damage
Before we set out to test whether p53 was involved in the induction of WRAP53α,
we first wanted to confirm that p53 protein was expressed in our cells in response to DNA
damage. Western blotting was used to detect and characterize which conditions prompted
an endogenous p53 response (and therefore which conditions might lead to p53-mediated
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transcriptional control of WRAP53α). It was predicted that HCT116 cells and U2OS cells
would elicit a p53 response to DNA damaging drugs cisplatin and doxorubicin, because
they possess wild-type p53, and that the K/O cell line, which features a targeted mutation
eliminating p53 gene expression (Bunz et al., 1999), would not. The SAOS-2 cell line was
not assayed for a p53 response, as it is accepted to be homozygous for null p53 (ATCC,
2008). As we expected, no p53 was detected in the K/O cell line, and p53 was detected 24
hours post-treatment with 35 μM cisplatin and 1 µM doxorubicin in cell lines with wildtype p53. The heightened level of p53 protein was sustained through 72 hours, with both
cisplatin and doxorubicin showing similar results in terms of band intensity (Figure 3.4).
This indicates that a p53/WRAP53α regulatory interaction could potentially be achieved—
and therefore detected—after treating U2OS and HCT116 cells with DNA damaging
agents cisplatin and doxorubicin.

ChIP demonstrates that p53 binds to the WRAP53α promoter
ChIP, which is able to detect DNA sequences bound by specific proteins, was used
to test whether or not p53 bound to any of our three sites of interest. First, to ensure that
each putative p53 binding site could be amplified from genomic DNA—and therefore to
confirm that non-quantitative PCR on ChIP samples was feasible—several different
genomic DNA samples were tested alongside the cloned WRAP53α promoter vector. We
found that our primer sets for each putative p53 binding site were indeed suitable to use on
genomic DNA, and therefore could be used to PCR amplify our final ChIP product in order
to determine whether or not each specific site had been pulled down by our anti-p53 (Figure
3.5).
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Table 3.1. As many as 66 transcription factors have putative binding sites on the WRAP53α promoter.
c-Myb
NFI/CTF
C/EBPβ
TFIID
POU2F1
Elk-1
TCF-4
c-Fos
Ik-1

GRβ
GR
C/EBPα
RXRα
LEF-1
NF-Y
PEA3
EBF
ELF-1

XBP-1
HNF-1C
NF-AT2
YY1
c-Ets-2
NF-1
ETF
NF-κB1
IRF-2

ENKTF-1
FOXP3
TFII-I
HNF-3α
IRF-1
T3R-β1
AP-1
NF-AT1

Pax-5
HNF-1B
STAT4
STAT1β
NF-AT1
PPARα/RXRα
c-Jun
RBP-Jκ

p53
GR-α
c-Ets-1
MAZ
HOXD9
MEF-2A
AhR/Arnt
ATF3

SRY
PRB
RelA
E2F-1
HOXD10
NF-κB
AR
VDR

TCF-4E
PRA
GATA-1
AP-2αA
RAR-β
HNF-4α
RAR-β/RXRα
PXR-1/RXRα

Table 3.1. A search of the WRAP53α promoter using the PROMO tool developed by ALGGEN led to the identification of 66 possible
transcription factors—one of them being p53—that could potentially bind to the 1,487 bp WRAP53α cloned sequence. *Results based
on Farré et al. (2003)
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A.

B.

Figure 3.3. As a tetramer, p53 binds DNA through two separate half-sites. A 2007 study by Brynczka et al. showed that, whether
inducing (A) or repressing (B), p53 binds with sequence specificity to two distinct half-sites separated by 0-13 bp. Larger letters
correspond to higher frequencies. A = adenosine; G = guanosine; C = cytidine; T = thymidine. *Image from Brynczka et al. (2007)

Table 3.2. Mismatch analysis implicated 3 sites that seemed most likely to be p53 binding sites.
Sequence
RRRC(A/T)(A/T)GYYY…
…RRRC(A/T)(A/T)GYYY
Site 1
ggcctagcccaaagctagata
Site 2
attcttgaaagtgcctccgggcttgcct
Site 3
cgccatggtagcgtccgcctaggtt
Site 4
cgccatgacaagtaagggcaagtaa
Site 5
tgacaagtaagggcaagtaa

# bp
Between

Preceding
Half Site A

Following
Half Site A

Preceding
Half Site B

Following
Half Site B

Total # Mismatches

0 - 13

RRR

YYY

RRR

YYY

--

1

1 mm

0 mm

0 mm

2 mm

3 mm

8

2 mm

3 mm

0 mm

0 mm

5 mm

5

2 mm

2 mm

2 mm

1 mm

7 mm

5

2 mm

2 mm

0 mm

2 mm

6 mm

0

1 mm

2 mm

0 mm

2 mm

5 mm
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Table 3.2. For each of the potential binding site pairs in the WRAP53α promoter, the relative fidelity to a perfect consensus sequence
(row 1) was evaluated in terms of mismatches for each criterion. The total number of mismatches for each putative site was calculated.
R = purine (adenosine/guanosine); Y = pyrimidine (cytidine/thymidine); mm = mismatch

Figure 3.4. Western blotting indicates that a p53 response starts within 24 hours after
DNA damage occurs and is sustained through 72 hours. For each of three cell lines
(HCT116, U2OS, and K/O), the p53 response to 35 μM cisplatin and 1 µM doxorubicin
was assayed at 24, 48, and 72 hours and compared to an untreated control. U2OS and
HCT116 cell lines possess a wild-type p53 gene, while the K/O cell line possesses a
targeted mutation eliminating the p53 gene entirely (Bunz et al., 1999). β-actin was used
as a loading control. UT = untreated
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Wrap
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Site 1
Site 2

75 bp

Site 3
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Figure 3.5. Each of the three putative binding sites is PCR amplified from genomic DNA.
The PCR product shown on a 3.5% gel depicts amplification of each putative binding site.
The amplified sequences range from 57 (site 1) to 75 (site 2) bp in length; site 3 is 69 bp
in length. Wrap = WRAP53α promoter vector DNA; C = genomic DNA derived from
COLO 205 cells; D, K, and S represent the genomic DNA of three different lab members

After establishing that each site could be PCR-amplified from genomic DNA, cells
were treated with 35 μM cisplatin or 1 µM doxorubicin for 24 hours, and cross-linked
chromatin was sheared to an optimal 200 – 1500 bp. The chromatin was incubated with
anti-p53 and immunoprecipitated with protein G-coupled magnetic beads, then cross-links
were reversed and the pulled-down chromatin was PCR-amplified with primers specific to
sites 1, 2, and 3 (Table 2.19). Because p53 is known to bind to the p21 promoter, p21
primers were used as a positive control, as was RNA Polymerase II, which is known to
bind to the GAPDH promoter (among other promoters). Negative controls consisted of an
IgG serum and a water-only immunoprecipitation. The Input sample did not undergo any
immunoprecipitation but was subject to PCR amplification of each site, as another positive
control indicating that our primers could PCR amplify the site from genomic DNA.
We found that, in response to treatment with 1 µM doxorubicin, p53 appeared to
bind to site 1 with a pixel intensity that was 2.4x greater than the negative control; this was
consistent with a p53/p21 interaction that was also 2.4x greater than the negative control.
However, p53 interactions at sites 2 and 3 were deemed unlikely at 1.5 and 1.8x greater
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than background, respectively (Figure 3.6). In response to treatment with 35 μM cisplatin,
p53 appeared to bind to sites 1, 2, and 3 with pixel intensities that were 2.4, 9.7, and 2.2x
greater than the negative control, respectively, while p53 bound to p21 with a pixel
intensity that was 2.5x greater than background (Figure 3.7). These results indicate that
p53 seems to bind to the WRAP53α promoter at the three sites we identified, and that the
degree and location of binding may be dependent on the type of DNA damage.

Figure 3.6. ChIP demonstrates that p53 protein binds to the WRAP53α promoter at site
1 in response to doxorubicin-induced damage. Cells were treated with 1 µM doxorubicin
for 24 hours and subject to ChIP. Following PCR, the ChIP end product was run on a 1%
agarose gel. Bold-faced text indicates which immunoprecipitation treatment was used, and
italicized text indicates which primers were used for PCR. Input chromatin was not
immunoprecipitated but was PCR amplified along with the immunoprecipitation (IP) end
results. No AB = no antibody, water only IP; RNAP = RNA Polymerase II
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Figure 3.7. ChIP demonstrates that p53 protein binds to the WRAP53α promoter at sites
1, 2, and 3 in response to cisplatin-induced damage. Cells were treated with 35 μM
cisplatin for 24 hours and subject to ChIP. Following PCR, the ChIP end product was run
on a 1% agarose gel. Bold-faced text indicates which immunoprecipitation treatment was
used, and italicized text indicates which primers were used for sequence-specific
amplification of a certain gene or site. Input chromatin was not immunoprecipitated but
was PCR amplified along with the IP end results. No AB = no antibody, water only IP;
RNAP = RNA Polymerase II

Site-directed mutagenesis yielded three mutants, each missing one p53 binding site
In order to determine whether deletions of each site would elicit an altered
WRAP53α DNA damage response at the promoter, three separate mutant WRAP53α
promoters were created via site-directed mutagenesis, each one missing a single putative
p53 binding site. Successful deletion of each binding site was confirmed with PCR (Figure
3.8). As compared to PCR-amplified wild-type putative binding sites 1, 2, and 3, which
were 57, 75, and 69 bp, respectively, the PCR-amplified mutant putative binding sites were
36, 47, and 43 bp, respectively. The mutations were further confirmed with sequencing
completed by Eton Bioscience.
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Figure 3.8. Each of the three putative binding sites was successfully deleted using sitedirected mutagenesis. PCR was carried out using primers flanking each binding site, and
the mutant PCR-amplified site was compared to its wild-type counterpart on a 3.5% gel.
For site 1 (A), a 21-bp deletion occurred; for site 2 (B), a 28-bp deletion occurred, and for
site 3 (C), a 26-bp deletion occurred.

The deletion of site 3 led to altered basal promoter activity
Transient transfection assays were used to determine the basal expression profile
of each mutant promoter, relative to the wild-type WRAP53α promoter. The purpose of
these transfections was to ensure that the mutant promoters were still displaying luciferase
expression, and also to identify any differences between wild-type WRAP53α basal
promoter activity and mutant WRAP53α basal promoter activity in unstressed conditions.
The amount of transfected reporter DNA was titrated in increasing amounts, from
0.1 to 0.5 µg per transfection, and the fold increase in expression was calculated relative to
samples receiving 0 µg of transfected reporter DNA. We predicted that, because p53 is not
significantly expressed until genotoxic stress occurs, basal promoter activity of each of the
mutants would remain similar to the wild-type WRAP53α promoter and would display a
parallel dose-dependent increase in luciferase activity upon receiving a larger
concentration of transfected reporter DNA. In the SAOS-2 cell line, none of the mutants’
expression profiles differed significantly from the wild-type promoter. Although luciferase
activity generally increased for all reporter DNAs in all cell lines in the expected manner,
dose-dependent upon the concentration of reporter DNA used in the transfection (with a
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notably more modest increase in SAOS-2 cells as compared to the other cell lines), the
deletion of site 3 led to a significantly reduced increase in luciferase activity in HCT116,
K/O, and U2OS cells (p = 0.0143) (Figure 3.9).

Sites 1, 2, and 3 are necessary for a typical response 24 hours post-DNA damage
To further test whether or not p53 interactions at our three identified binding sites
led to actual transcriptional regulation at the promoter in response to DNA damage, we
used additional transient transfection assays with luciferase reporter assays. Cells were
either untreated or treated with 1 µM doxorubicin (Figure 3.10) or 35 μM cisplatin (Figure
3.11) to elicit a DNA damage response and harvested after 24 or 48 hours. It was predicted
that HCT116 and U2OS cells, which possess wild-type p53, would display a typical
increase in promoter activity in response to DNA damage at both 24 and 48 hours in the
wild-type promoter; it was also predicted that, if p53 is binding the WRAP53α promoter to
induce gene expression in response to DNA damage, then one or more of the mutant
promoters would fail to display a typical induction. In order to define what a p53-dependent
induction looks like as a positive control, identical transfections were conducted using the
BAX and p21 promoters, where p53 is known to bind and induce gene expression response
to DNA damage. In U2OS cells, treatment with doxorubicin showed a 1.5- to 3.5-fold
increase in BAX promoter activity, while treatment with cisplatin led to a 2-fold increase.
p21 promoter activity increased 1.5-fold and 1.6-fold upon treatment with 35 μM cisplatin
and 1 µM doxorubicin, respectively. In HCT116 cells, BAX induction showed a 1.6-fold
increase upon treatment with both 35 μM cisplatin and 1 µM doxorubicin (unpublished
work completed by R. Bongalonta, 2019; data not shown).
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Figure 3.9. Increased luciferase activity was detected upon increasing the amount of
transfected reporter DNA in a dose-dependent manner. Fold change in relative light units
per second (RLU/s) was calculated for each reporter DNA based on luminometer readings
and represents relative luciferase activity in HCT116 (A), U2OS (B), K/O (C), and SAOS2 (D) cells. Differently shaded bars represent the addition of 0.0, 0.1, 0.25, and 0.5 µg of
reporter DNA per transfection reaction respectively. Fold change in expression relative to
cells receiving 0.0 µg (1.00) was calculated. Significance was calculated for each reporter
DNA relative to the corresponding WrapAlpha value at that concentration using the
nonparametric t-test alternative, the Wilcoxon Rank Sum Test. A p-value (α=0.05) of
0.0143 is denoted by “*”. Standard error of the mean is indicated by error bars (n = 4).
WrapAlpha = wild-type WRAP53α promoter; Site 1, Site 2, and Site 3 = WRAP53α
promoter missing sites 1, 2, and 3, respectively
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After a 24 hour incubation with 1 µM doxorubicin, neither the SAOS-2 nor the K/O
cells experienced induction with any reporter DNA, although at 48 hours, there was a 1.5fold increase in promoter activity for the Site 2 mutant in K/O cells. No inductions
exceeding 1.5-fold (Site 2 mutant, 48 hours) were observed in HCT116 cells. In U2OS
cells, the wild-type promoter showed a two-fold increase in expression in response to
doxorubicin, which was characteristic of previous experiments. This increase seemed to
occur with the site 2 and site 3 mutants, though the variance was too great to determine
wither this effect was statistically significance. However, a statistically significant loss of
induction occurred in the site 1 mutant at 24 hours. No fold-change in WRAP53α activity
was observed in U2OS cells 48 hours post-treatment with doxorubicin, even in the wildtype promoter (Figure 3.10).
Identical experiments done in cells 24 or 48 hours post-treatment with 35 μM
cisplatin were more inconclusive, with no statistically significant inductions detected in
response to DNA damage, even in the wild-type promoter. An induction was seen in the
site 3 mutant in HCT116 cells at 24 hours but was not determined to be statistically
significant due to large variance (Figure 3.11).

A mutant missing sites 1 and 2 is not induced in response to doxorubicin
Following initial DNA damage transfections, a new mutant was made from the formerly
functional Site 2 mutant plasmid to determine whether or not p53 might bind redundantly.
Site-directed mutagenesis was used to remove both sites 1 and 2, and transient transfections
with subsequent luciferase reporter assays in U2OS cells treated for 24 hours with 1 µM
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doxorubicin showed that this double mutant was induced even less than the site 1 mutant
(Figure 3.12).

Exogenous overexpression of p53 leads to transcriptional repression
In order to determine whether or not the loss of induction observed in the mutants
in response to DNA damage could be modeled through exogenous overexpression of p53
expression vector in unstressed cells, we used transient transfections combined with
luciferase reporter assays while increasing the amount of transfected p53. In cells with
wild-type p53 status (HCT116 and U2OS), transfections with the wild-type WRAP53α
promoter led to repression of promoter activity, in direct contrast to the induction seen in
endogenous p53 experiments. However, in cells with null or knock-out p53 status (SAOS2 and K/O), transfections with the wild-type WRAP53α promoter led to increased promoter
activity. In general, the site 1 mutant behaved much like the wild-type promoter, indicating
that a response to exogenous overexpression of p53 does not rely on site 1. The site 2
mutant also behaved much like the wild-type promoter, with notable peaks of activity
reliably occurring in the Site 2 mutant upon exposure to 0.1 μg of transfected p53. We
found that the site 3 mutant experienced significant repression in response to p53 in all four
cell lines (Figure 3.13), agreeing with the basal expression experiments (Figure 3.9). We
also noticed a peak in promoter activity in the site 2 mutant in response to 0.1 μg of p53
expression vector.
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Figure 3.10. Deletions in site 1 led to an altered DNA damage response in U2OS cells in
response to 1 µM doxorubicin. Transiently transfected cells were harvested 24 hours after
treatment with doxorubicin and promoter activity was determined in RLU/s. Cell lines used
included those with wild-type p53 status: HCT116 (A) and U2OS (B), and those with
knock-out or null p53 status: K/O (C) and SAOS-2 (D). Fold change in expression relative
to untreated cells (1.00) was calculated. For each reporter DNA, doxorubicin-treated
expression levels were tested relative to untreated cells, using a one-sided Wilcoxon Rank
Sum Test. A statistically significant induction was denoted by “*” (α = 0.05; p = 0.0143; n
= 4). WrapAlpha = wild-type WRAP53α promoter; Site 1, Site 2, and Site 3 = WRAP53α
promoter with targeted deletions removing putative binding sites 1, 2, and 3, respectively

82

B.

HCT116
3.50
3.00
2.50
2.00
1.50
1.00
0.50
0.00

Fold change in RLU/s

Fold change in RLU/s

A.

U2OS

3.50
3.00
2.50
2.00
1.50
1.00
0.50
0.00

Reporter DNA
Untreated

48 hours

Untreated

D.

K/O
3.50
3.00
2.50
2.00
1.50
1.00
0.50
0.00

Fold change in RLU/s

Fold change in RLU/s

C.

24 hours

Reporter DNA

24 hours

48 hours

SAOS-2

3.50
3.00
2.50
2.00
1.50
1.00
0.50
0.00

Reporter DNA
Untreated

24 hours

Reporter DNA

48 hours

Untreated

24 hours

48 hours

Figure 3.11. Cisplatin-treated U2OS cells had less dramatic changes in promoter activity
but show a difference in each mutant relative to the wild-type promoter. After treatment
with 35 μM cisplatin, only the WRAP53α promoter in U2OS cells showed any induction.
Transiently transfected cells were harvested 24 or 48 hours following treatment with
cisplatin and promoter activity was determined in RLU/s via luciferase reporter assays.
Fold change in expression relative to untreated cells (1.00) was calculated. No statistically
significant differences were detected with a Wilcoxon Rank Sum Test (n=4, α = 0.05).
WrapAlpha = wild-type WRAP53α promoter; Site 1, Site 2, and Site 3 = WRAP53α
promoter with targeted deletions removing putative binding sites 1, 2, and 3, respectively
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Figure 3.12. DNA damage induced expression of the wild-type promoter, which was
impaired upon deleting site 1 and lost entirely upon deleting both sites 1 and 2.
Transiently transfected U2OS cells were harvested 24 hours after treatment with 1 µM
doxorubicin and promoter activity was determined in RLU/s via luciferase reporter assays.
Fold change in expression relative to untreated cells (1.00) was calculated. For each
reporter DNA, doxorubicin-treated expression levels were tested relative to untreated cells,
using a one-sided Wilcoxon Rank Sum Test. A statistically significant induction was
detected for the wild-type promoter in U2OS cells (α = 0.05; p = 0.0143; n = 4). WrapAlpha
= wild-type WRAP53α promoter; Site 1, Site 2, and Site 3 = WRAP53α promoter with
targeted deletions removing putative binding sites 1, 2, and 3, respectively; Site 1,2 =
WRAP53α promoter missing sites 1 and 2
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Figure 3.13. Exogenous overexpression of p53 did not indicate that the three binding
sites are important for a protein/DNA interaction. Transfected cells were harvested 24
hours after treatment with 0, 0.1, 0.25, and 0.5 μg of p53 expression vector. Promoter
activity was determined in RLU/s via luciferase reporter assays. Cell lines used included
those with wild-type p53 status: HCT116 (A) and U2OS (B), and those with knock-out or
null p53 status: K/O (C) and SAOS-2 (D). Fold change in expression relative to cells
receiving 0.0 µg (1.00) was calculated. For each reporter DNA, RLU/s corresponding to
increasing levels of transfected p53 were tested relative to cells receiving 0 μg of
transfected p53, using a one-sided Wilcoxon Rank Sum Test. WrapAlpha = wild-type
WRAP53α promoter; Site 1, Site 2, and Site 3 = WRAP53α promoter with targeted
deletions removing putative binding sites 1, 2, and 3, respectively. *Indicates a p-value of
0.0143 (α = 0.05; n = 4)
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CHAPTER IV
CONCLUSIONS

p53 was first reported to be regulated post-transcriptionally by the mRNA transcript
of its antisense gene, WRAP53α, in 2009 (Mahmoudi et al.). When siRNA-mediated knockdown of the WRAP53α transcript occurred, the p53 transcript was degraded rapidly and
levels of translation were not sufficient enough to elicit a tumor suppressive effect. This
series of experiments have given insight into the behavior of the WRAP53α promoter,
particularly its response to DNA damage and its interaction with p53 protein. Our initial
experiments support previous work by Yuan et al. (2011), which shows that WRAP53α is
induced in response to DNA damage. However, we have extended these results to show
that it is transcriptional upregulation that ultimately leads to this induction; furthermore,
we have shown p53, as a transcription factor, binds to the WRAP53α promoter at several
different locations, leading to increased mRNA production in response to DNA damage.

p53 was identified as a putative binding factor of the WRAP53α promoter
After preliminary experiments showed that WRAP53α promoter activity increased
in response to DNA damage, we sought to identify the responsible DNA-binding
transcription factors. We input the 1,487 bp cloned promoter sequence into the PROMO
software, which identifies putative transcription factors (Farré et al, 2003). As many as 66
transcription factors were identified. We chose to pursue the possibility of p53-mediated
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transcriptional regulation due to the established functional and geographic relationship
between p53 and WRAP53α, however, there is likely much to be learned from similar
experiments with other possible binding factors. These other binding factors could be
responsible for basal expression of WRAP53α or contributing to the gene’s induction upon
DNA damage. In addition to regulating WRAP53α, these factors could lead to a synergistic
or an antagonistic effect when p53 binds.

ChIP demonstrates that p53 binds to the WRAP53α promoter
ChIP is a useful technique for identifying protein/DNA interactions that could
potentially occur in vivo. We used two DNA damaging agents, doxorubicin and cisplatin,
to initiate a p53 response in U2OS cells, then cross-linked proteins with formaldehyde
fixation before PCR amplifying our ChIP final product with primers specific to our three
identified sites. According to our ChIP results, which were supported by transient
transfection and luciferase assays with mutant promoters, doxorubicin, a topoisomerase II
inhibitor, promotes binding at site 1, while cisplatin, a cross-linking agent, appears to
promote binding at sites 1, 2, and 3.
This information supports a recurring theme in p53 literature: context matters. Not
only might different forms of p53 bind to different sites (Marouco et al., 2013), dictating
whether a cell undergoes DNA damage repair, cell cycle arrest, or apoptosis, but the
consequence of p53 binding to each site could be further calibrated by a large number of
combinations of post-translational modifications, all optimized to stimulate a unique set of
target genes, and all influenced by the activity of other binding factors, siRNAs, and
epigenetic remodelers—ultimately such complicated networks could be induced by
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specific categories of genotoxic stressors. This idea of a DNA damage-specific p53
response is supported by the work of Aoubala et al. (2011), which found that doxorubicin
promotes translation of the Δ133p53α isoform, subsequently leading to apoptosis and G1—
but not G2—cell cycle arrest. Additionally, in a similar study, activated p53 target genes
were compared between cisplatin- and adriamycin-treated cells, with the conclusion that
different drugs induce different classes of genes in an isoform-specific way (Avery-Kiejda
et al., 2008). For example, in the Mel-RM cell line, treatment with adriamycin led to p53dependent induction of p21 and PUMA, but treatment with cisplatin only led to p53induction of p21; similarly, the Δ40p53 isoform inhibited p53-dependent transcription of
p21 and PUMA whereas the p53β isoform induced transcription (Avery-Kiejda et al.,
2008).

The deletion of site 3 led to altered basal promoter activity
In order to see if deletion of each site affected promoter activity, we used
transfection and luciferase assays. However, we first wanted to characterize basal
expression for each mutant promoter. We found that the loss of site 3 led to a decrease in
WRAP53α expression relative to the wild-type or site 1 and 2 mutants in all tested cell lines,
including those with knock-out or null p53. Given that this occurred regardless of p53
status, we believe another binding factor could be interacting with site 3, which could be
tested. Upon re-entering site 3 in the PROMO software (along with 50 bp flanking the site),
18 putative binding factors were identified (including, of course, p53). Binding sites for
two of these transcription factors—Pax-5 and glucocoricoid receptor (GR) alpha—partially
overlap site 3 and provide a starting point for understanding WRAP53α basal expression.
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A mutant missing sites 1 and 2 loses typical induction in response to doxorubicin
When cells transfected with each mutant were treated with doxorubicin and
compared to their wild-type counterparts, we found that site 1 seemed important for an
induction in response to doxorubicin 24 hours post-treatment in U2OS cells. In order to
determine whether p53 could possibly bind redundantly (with preference for site 1), we
deleted both sites 1 and 2. We found that a mutant missing these two sites may be induced
even less than a mutant missing just site 1. This further implicates site 1 as being
instrumental for a DNA damage-mediated induction of the WRAP53α promoter but also
supports the possibility of a redundant p53/WRAP53α interaction—perhaps p53 binds
preferentially to site 1, the sequence of which is closer to consensus, in response to
doxorubicin, but can also bind site 2 for an effective DNA damage response. Given that
the necessary ratio of transcripts needed to stabilize the p53 message is 1 WRAP53α per
100 p53 transcripts (Mahmoudi et al., 2009), it is possible that a 1.5-fold increase as
compared to a 2- or 3-fold increase could still be physiologically significant. This is an
experiment that could be tested via CRISPR gene editing and ChIP-qPCR.

Exogenous overexpression of p53 may lead to transcriptional repression
As one way to determine whether p53 would induce expression of the WRAP53α
in the absence of DNA damage, we transfected a p53 expression vector into unstressed
cells. Experiments increasing the amount of transfected p53 vector were largely
inconclusive. No convincing inductions were seen in wild-type p53 cell lines—in fact, if
anything, we noticed repression in response to exogenous p53 expression in these cells. In
addition, in all cell lines, the absence of site 3 led to a decrease in promoter activity. One
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possible explanation for this effect is that we do not know how the p53 we transfected is
expressed and modified, meaning it could elicit different effects than endogenous, stressresponse p53. Since we do not know how biologically relevant exogenous overexpression
of p53 is, isoform- or modification-specific Western blotting will be necessary to
characterize the expression of the transfected p53 vector in order to determine whether it
is expressed the same way that endogenous p53 is—it may be that certain modifications of
p53 protein lead to repression of WRAP53α.

Disparate results in U2OS vs. HCT116 cells may indicate a tissue-specific response
Surprisingly, although an induction of WRAP53α was seen in U2OS cells (and
subsequently lost in the Site 1 and Sites 1 & 2 mutant), no clear induction was seen in
HCT116 cells, which possess wild-type p53. In fact, these cells behaved much like the p53null cell line which they gave rise to. One possible explanation for this disparity is that
WRAP53α expression may be linked to tissue type and dependent on the expression of
other genes with differing expression patterns in HCT116 and U2OS cells; this seems
feasible particularly given that the cell lines used are tumor-derived and could be
characterized by unknown genomic aberrations or regulatory anomalies.
Furthermore, HCT116 cells are reported to be chemo-resistant to doxorubicin and
cisplatin due to genetic defects in the DNA mismatch repair system (Sergent et al., 2001;
Li, Liu, Yu, and Yu, 2015), meaning that DNA damage may not even be recognized, let
alone communicated via the appropriate intra-cellular cascade that would result in
WRAP53α induction. Additionally, Avery-Kiejda et al. (2008) found that different drugs
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led to distinct p53 targets being activated, leading to different cellular outcomes, in
different tissues.

A p53/WRAP53α interaction could be a model for anti-parallel gene function
NATs were once thought to be relatively rare and to only occur in viral or
prokaryotic genomes (Rosikiewicz & Makalowska, 2016). However, they are now
understood to occur in up to 30% of the human genome and are beginning to be considered
a novel mode of regulation, allowing transcriptional, post-transcriptional, and even
epigenetic regulation of their antisense genes (Rosikiewicz & Makalowska, 2016). Recent
studies have shown that NATs are implicated in carcinogenesis (Berteaux et al., 2008;
Dolnick, Angelino, Dolnick, & Sufrin, 2003; Oto et al., 2007; Rao et al., 2014; Rossignol,
Vaché, & Clottes, 2002; Yao et al., 2004; Yu et al., 2008; S.C. Zhang et al., 2007). Our
study emphasizes the importance of anti-parallel transcription units and demonstrates how
these interactions could lead to antisense genetic regulation.

WRAP53α mutations or dysregulation may contribute to cancer
WRAP53β is a variant of the WRAP53 gene with a distinct alternative start site from
WRAP53α. Of the WRAP53 variants, WRAP53β is the only one known to code for a
functional WD40-like protein (Mahmoudi et al., 2010). This protein has been identified as
scaffold protein associated with Cajal body formation, telomere elongation, and repair of
double-stranded DNA breaks (Henriksson & Farnebo, 2015). Because it is protein-coding,
much work has been done on the impact of WRAP53β expression and localization in many
types of cancers and diseases (Cao, Wang, Zhang, & Lou, 2016; Garcia-Closas et al., 2007;
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Henriksson & Farnebo, 2015; Lan et al., 2009; Mahmoudi, Henriksson, Farnebo, Roberg,
& Farnebo M.et al., 2011; Medrek et al., 2013; Schildkraut et al., 2009; ; Sun et al., 2014;
Yuan et al., 2017; Zhu, Ding, Chen, Song, & Yao, 2018). But pathologies involving deregulated WRAP53α have only just begun to be examined. Methylation of the WRAP53α
promoter has been associated with poorer survival rates in non-small cell lung cancer
patients with wild-type p53 status (Kim et al., 2018).
Additionally, methylation status of the WRAP53α promoter was linked to ethnicity
and pesticide exposure in a Mexican population (Paredes-Céspedes et al., 2019),
supporting the need for studies investigating WRAP53α functioning in response to
environmental carcinogenic stressors, like pesticides, that might lead to deregulation of a
p53/WRAP53α DNA damage response and ultimately contribute to carcinogenesis. Such
stressors include direct exposure to UV radiation, tobacco-associated mutagens, and
environmental pollutants, but also indirect lifestyle factors, including poor diet and overuse
of antibiotics, which promote an oncogenic gut microbiome with disproportionate ratios of
cancer-associated bacteria (e.g., Salmonella typhi, Helicobacter pylori, and Bacteroides
fragilis) (Helmink, Wadud Khan, Hermann, Gopalakrishnan, & Wargo, 2019). These
bacteria promote tumor development by secreting genotoxins and reactive oxygen species
(ROS), in addition to maintaining chronic gut inflammation and altering signaling
pathways (Helmink et al., 2019).
It is established that approximately 50% of cancers possess a p53 mutation
(Bieging, Mello, & Attardi, 2014; DeFromentel & Soussi, 1992). However, in cancers with
wild-type p53 protein, p53 pathways are often de-regulated. Our findings raise the
possibility that a distinct class of cancers exists featuring mutations in p53 binding sites on
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the WRAP53α promoter while possessing wild-type p53 (the strand antiparallel to the
WRAP53α promoter contains a p53 intron). Such mutations would not permit p53 protein
to bind despite having a wild-type structure. Furthermore, any mutation in WRAP53α that
overlaps the homology to the first exon of p53 may affect post-transcriptional mRNA
hybridization and subsequent p53 transcript stability, preventing apoptosis, DNA damage
repair, or cell cycle arrest.

Further research is needed to strengthen and expand our results
So far, our findings are preliminary and essentially limited in scope: in response to
doxorubicin, p53 seems to bind to a specific site on the WRAP53α promoter, while in
response to cisplatin, it appears to bind to three specific sites. Deleting these sites may lead
to impaired induction in response to DNA damage, resulting in an inability to stabilize the
p53 transcript. Table 4.1 summarizes the next steps that can be taken to expand upon these
findings.

A positive feedback loop may exist between p53 and WRAP53α
Although much remains to be validated and extended, a major implication of these
findings is the development of what may be a positive feedback loop dependent upon
WRAP53α mRNA’s ability to stabilize the p53 mRNA transcript and p53 protein’s ability
to transcriptionally stimulate WRAP53α mRNA production. Notably, there is precedent for
such positive feedback loops wherein p53 induces its own inducer. This is demonstrated
by the interaction between p53 and Wig-1, a p53 target gene protein product, which binds
to an AU element in the 3’ UTR of the p53 mRNA transcript, conveying stability and
protection from de-adenylation (Vilborg et al., 2009).
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As of 2005, p53 had been implicated in at least seven negative feedback loops
(including one with Mdm2) and at least three positive feedback loops (Harris & Levine,
2005), though studies investigating miRNAs were not included in this study. Harris and
Levine (2005) predict that some feedback loops may be turned on or off in different tissue
types or stages of development. Furthermore, they predicted that this propensity for
feedback loops may be a convenient way for p53 to expand its cellular network, connecting
to signal transduction pathways in a variety of functions (Harris & Levine, 2005). Figure
4.1 illustrates our proposed mechanism of positive feedback loop formation.
Notably, this figure indicates what may happen in a functional p53/WRAP53α
circuit. Mutations in p53 may prevent this interaction from occurring, which would lead to
tumorigenesis, or they may enhance this interaction through GOF, resulting in an
accumulation of mutant p53. As the next CDC mortality report is released, cancer is
expected to surpass cardiovascular disease for the first time ever as the number one killer
of Americans. Despite record-breaking funding for cancer research, age-adjusted rates of
cancer have either plateaued or increased (CDC, 2002; CDC, 2009; CDC, 2013), indicating
a fundamental paradox between the quantity and quality of cancer research and its ability
to be applied to prevention and treatment best practices. The ability to block mutant p53
GOF or artificially induce genes crucial to inactivated tumor suppressor pathways in
response to common genotoxic stressors are just a few ways the findings in this study could
prove useful to cancer treatment and prevention in the future. However, for a condition
killing 9.6 million people in 2018 (WHO, 2018a), “a few ways” could translate into more
effective treatment and prevention strategies, less severe economic burdens, and overall
more successful health outcomes for a significant population.
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Table 4.1. Our next experiments will aim to solidify and expand upon preliminary findings.
Question
Rationale
Experimental Approach
ChIP-qPCR can give more information on
ChIP-qPCR
the strength of a p53/WRAP53α interaction
Do more precise methods in a variety of
WRAP53α has been studied in pulmonary
tissue types confirm our preliminary
tissue (Kim et al., 2018; Paredes-Céspedes et Similar experiments in a cohort of other
results?
al., 2019), which might respond better to
cell lines
cisplatin and doxorubicin than HCT116 cells
Western blots with specific antibodies
Do different isoforms of p53 bind to
Some evidence for context-dependent
sensitive enough to distinguish between
different sites?
binding
isoforms and PTMs
Mutant p53 accumulates to high levels in
Does mutant p53 utilize these same
tumors; despite often losing DNA binding
EMSA or ChIP with mutant p53 cell
binding sites?
capabilities, mutant p53 protein is subject to
lines
GOF
Using a new cohort of DNA damaging
agents
Evidence exists for context-specific binding;
one major goal would be testing common
CRISPR gene editing + qPCR to look at
Is binding site preference truly damagecarcinogens on wild-type p53 and saving
the effect of mutations on transcript
dependent?
chemotherapy drugs for mutant p53, for a
production
more realistic model
Repeating ChIP and EMSA to determine
binding
Table 4.1. Remaining questions are provided, along with the rationale for each question and an experimental approach that would begin
to answer these questions. CRISPR = clustered regularly interspaced short palindromic repeats; EMSA =electrophoretic mobility shift
assay; qPCR = quantitative PCR

(1) DNA damage occurs

(2) Increase in p53 protein
p53 protein, which is constitutively
expressed at low levels, is initially
activated in response to DNA
damage via phosphorylation by
ATM, etc.

(3) Increased binding to the
WRAP53α promoter
We propose that p53 acts as a
transcription factor, leading to
increased WRAP53α production

(6) Increase in p53 mRNA
p53 mRNA levels increase in
response to DNA damage, leading
to more p53 protein

(4) Increase in WRAP53α mRNA
If p53 is acting as a transcription
factor, its interaction at the WRAP
promoter would be self-serving,
allowing for more WRAP53α
mRNA to be produced

(5) Increased hybridization of
mRNAs
Hybridization between WRAP53α
and p53 mRNAs has been shown to
increase p53 mRNA stability

Figure 4.1. We propose that a positive feedback loop may exist between p53 and
WRAP53α in response to DNA damage. An initial DNA damaging event is indicated by
the yellow lightning bolt. Subsequent events are shown by navy boxes and gray arrows.
We propose that a positive feedback loop is established wherein stabilization of p53 protein
leads to upregulation of WRAP53α mRNA, which, in turn, leads to enhanced retention of
p53 transcripts, allowing heightened translation and ultimate protein accumulation that is
in accordance with a p53 response.
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